0000320017-24-000031.txt : 20240509 0000320017-24-000031.hdr.sgml : 20240509 20240509161347 ACCESSION NUMBER: 0000320017-24-000031 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 82 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LISATA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0000320017 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 222343568 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33650 FILM NUMBER: 24930786 BUSINESS ADDRESS: STREET 1: 110 ALLEN ROAD STREET 2: SECOND FLOOR CITY: BASKING RIDGE STATE: NJ ZIP: 07920 BUSINESS PHONE: 908-229-2590 MAIL ADDRESS: STREET 1: 110 ALLEN ROAD STREET 2: SECOND FLOOR CITY: BASKING RIDGE STATE: NJ ZIP: 07920 FORMER COMPANY: FORMER CONFORMED NAME: CALADRIUS BIOSCIENCES, INC. DATE OF NAME CHANGE: 20170808 FORMER COMPANY: FORMER CONFORMED NAME: Caladrius Biosciences, Inc. DATE OF NAME CHANGE: 20150608 FORMER COMPANY: FORMER CONFORMED NAME: NeoStem, Inc. DATE OF NAME CHANGE: 20060906 10-Q 1 lsta-20240331.htm 10-Q lsta-20240331
000032001712/312024Q1falsehttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrentP1Y.33xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pure00003200172024-01-012024-03-3100003200172024-05-0900003200172024-03-3100003200172023-12-3100003200172023-01-012023-03-310000320017us-gaap:CommonStockMember2022-12-310000320017us-gaap:AdditionalPaidInCapitalMember2022-12-310000320017us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000320017us-gaap:RetainedEarningsMember2022-12-310000320017us-gaap:TreasuryStockCommonMember2022-12-310000320017us-gaap:ParentMember2022-12-310000320017us-gaap:NoncontrollingInterestMember2022-12-3100003200172022-12-310000320017us-gaap:RetainedEarningsMember2023-01-012023-03-310000320017us-gaap:ParentMember2023-01-012023-03-310000320017us-gaap:CommonStockMember2023-01-012023-03-310000320017us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000320017us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000320017us-gaap:CommonStockMember2023-03-310000320017us-gaap:AdditionalPaidInCapitalMember2023-03-310000320017us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000320017us-gaap:RetainedEarningsMember2023-03-310000320017us-gaap:TreasuryStockCommonMember2023-03-310000320017us-gaap:ParentMember2023-03-310000320017us-gaap:NoncontrollingInterestMember2023-03-3100003200172023-03-310000320017us-gaap:CommonStockMember2023-12-310000320017us-gaap:AdditionalPaidInCapitalMember2023-12-310000320017us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000320017us-gaap:RetainedEarningsMember2023-12-310000320017us-gaap:TreasuryStockCommonMember2023-12-310000320017us-gaap:ParentMember2023-12-310000320017us-gaap:NoncontrollingInterestMember2023-12-310000320017us-gaap:RetainedEarningsMember2024-01-012024-03-310000320017us-gaap:ParentMember2024-01-012024-03-310000320017us-gaap:CommonStockMember2024-01-012024-03-310000320017us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000320017us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000320017us-gaap:CommonStockMember2024-03-310000320017us-gaap:AdditionalPaidInCapitalMember2024-03-310000320017us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000320017us-gaap:RetainedEarningsMember2024-03-310000320017us-gaap:TreasuryStockCommonMember2024-03-310000320017us-gaap:ParentMember2024-03-310000320017us-gaap:NoncontrollingInterestMember2024-03-310000320017us-gaap:FurnitureAndFixturesMember2024-03-310000320017us-gaap:ComputerEquipmentMember2024-03-310000320017us-gaap:ComputerSoftwareIntangibleAssetMember2024-03-310000320017us-gaap:RoyaltyMember2024-01-012024-03-310000320017us-gaap:CorporateDebtSecuritiesMember2024-03-310000320017us-gaap:CorporateDebtSecuritiesMember2023-12-310000320017us-gaap:CommercialPaperMember2024-03-310000320017us-gaap:CommercialPaperMember2023-12-310000320017us-gaap:MoneyMarketFundsMember2024-03-310000320017us-gaap:MoneyMarketFundsMember2023-12-310000320017us-gaap:USStatesAndPoliticalSubdivisionsMember2024-03-310000320017us-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-310000320017us-gaap:ComputerEquipmentMember2023-12-310000320017us-gaap:LeaseholdImprovementsMember2024-03-310000320017us-gaap:LeaseholdImprovementsMember2023-12-310000320017us-gaap:EmployeeStockOptionMember2024-01-012024-03-310000320017us-gaap:EmployeeStockOptionMember2023-01-012023-03-310000320017us-gaap:WarrantMember2024-01-012024-03-310000320017us-gaap:WarrantMember2023-01-012023-03-310000320017us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310000320017us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310000320017us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-03-310000320017us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000320017us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-03-310000320017us-gaap:FairValueMeasurementsRecurringMember2024-03-310000320017us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310000320017us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000320017us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310000320017us-gaap:FairValueMeasurementsRecurringMember2023-12-310000320017lsta:AtTheMarketOfferingAgreementMember2021-06-040000320017us-gaap:SubsequentEventMemberlsta:AtTheMarketOfferingAgreementMember2024-05-010000320017us-gaap:SubsequentEventMember2024-05-010000320017lsta:AtTheMarketOfferingAgreementMember2024-03-210000320017lsta:AtTheMarketOfferingAgreementMember2024-01-012024-03-310000320017lsta:AtTheMarketOfferingAgreementMember2021-06-042024-03-310000320017lsta:AtTheMarketOfferingAgreementMember2021-06-042024-03-2400003200172023-01-012023-12-310000320017us-gaap:RestrictedStockMember2024-01-012024-03-310000320017us-gaap:RestrictedStockMember2023-01-012023-03-310000320017srt:MinimumMemberus-gaap:RestrictedStockMember2024-01-012024-03-310000320017us-gaap:RestrictedStockMembersrt:MaximumMember2024-01-012024-03-310000320017us-gaap:RestrictedStockMember2023-12-310000320017us-gaap:RestrictedStockMember2024-03-310000320017us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310000320017us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310000320017us-gaap:RestrictedStockUnitsRSUMember2023-12-310000320017us-gaap:RestrictedStockUnitsRSUMember2024-03-3100003200172024-03-210000320017us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310000320017us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310000320017us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310000320017us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310000320017us-gaap:EmployeeStockOptionMember2024-03-310000320017us-gaap:EmployeeStockOptionMember2024-01-012024-03-310000320017us-gaap:EmployeeStockOptionMember2023-01-012023-03-310000320017us-gaap:DomesticCountryMember2023-12-310000320017us-gaap:DomesticCountryMember2022-12-310000320017us-gaap:DomesticCountryMemberlsta:CENDMember2023-12-310000320017us-gaap:DomesticCountryMemberlsta:CENDMember2022-09-150000320017us-gaap:StateAndLocalJurisdictionMemberlsta:CENDMember2022-09-150000320017lsta:CENDMember2023-01-012023-12-310000320017lsta:CENDMember2023-12-310000320017us-gaap:ForeignCountryMemberlsta:CENDMember2023-12-310000320017us-gaap:ForeignCountryMemberlsta:CENDMember2022-12-310000320017us-gaap:DomesticCountryMemberus-gaap:ResearchMember2023-12-310000320017us-gaap:StateAndLocalJurisdictionMemberus-gaap:ResearchMember2023-12-310000320017us-gaap:StateAndLocalJurisdictionMemberus-gaap:NewJerseyDivisionOfTaxationMember2023-12-310000320017us-gaap:StateAndLocalJurisdictionMemberus-gaap:NewJerseyDivisionOfTaxationMember2022-12-310000320017us-gaap:StateAndLocalJurisdictionMemberus-gaap:CaliforniaFranchiseTaxBoardMember2023-12-310000320017us-gaap:StateAndLocalJurisdictionMemberus-gaap:CaliforniaFranchiseTaxBoardMember2022-12-310000320017us-gaap:StateAndLocalJurisdictionMemberus-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember2023-12-310000320017us-gaap:StateAndLocalJurisdictionMemberus-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember2022-12-3100003200172024-03-042024-03-0400003200172023-04-052023-04-050000320017srt:MinimumMember2024-01-012024-03-310000320017srt:MaximumMember2024-01-012024-03-310000320017lsta:LingmedLimitedMember2024-03-252024-03-250000320017lsta:LingmedLimitedMember2024-03-250000320017lsta:ImpiloMember2023-07-310000320017lsta:ImpiloMember2023-10-0300003200172024-03-152024-03-150000320017lsta:ImpiloMember2024-03-310000320017lsta:ImpiloMember2023-12-310000320017us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMemberlsta:SanfordBurnhamPrebysMember2015-12-310000320017lsta:SanfordBurnhamPrebysMemberlsta:ImpiloMember2023-10-030000320017lsta:SanfordBurnhamPrebysMember2024-03-310000320017lsta:QiluMemberlsta:ExclusiveLicenseAndCollaborationAgreementMemberus-gaap:LicenseMember2021-02-280000320017lsta:QiluMemberlsta:ExclusiveLicenseAndCollaborationAgreementMemberus-gaap:LicenseMember2022-09-142022-09-140000320017lsta:QiluMembersrt:MinimumMemberlsta:ExclusiveLicenseAndCollaborationAgreementMemberus-gaap:LicenseMember2021-02-280000320017lsta:QiluMemberlsta:ExclusiveLicenseAndCollaborationAgreementMemberus-gaap:LicenseMembersrt:MaximumMember2021-02-280000320017lsta:QiluMemberlsta:ExclusiveLicenseAndCollaborationAgreementMemberus-gaap:LicenseMember2021-02-012021-02-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
FORM 10-Q
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the Quarterly Period Ended March 31, 2024
 
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the Transition Period from __________________   to _________________________
 
Commission File Number 001-33650
 
LISATA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)


Delaware22-2343568
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
  
110 Allen Road, 2nd Floor, Basking Ridge, New Jersey
07920
(Address of principal executive offices)(zip code)
 
Registrant’s telephone number, including area code: 908-842-0100
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareLSTA
The Nasdaq Capital Market
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐     No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.
ClassOutstanding as of May 9, 2024
Common stock, $0.001 par value per share8,307,433 shares



CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report (this “Quarterly Report”) contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. When used in this Quarterly Report, statements that are not statements of current or historical fact may be deemed to be forward-looking statements, including, without limitation, all statements related to any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals; any other statements of expectations, plans, intentions or beliefs; and any statements of assumptions underlying any of the foregoing. Without limiting the foregoing, the words “plan,” “project,” “forecast,” “outlook,” “intend,” “may,” “will,” “expect,” “anticipate,” “likely,” “believe,” “could,” “anticipate,” “estimate,” “continue,” “target” or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity or our achievements or industry results, to be materially different from any future results, performance, levels of activity or our achievements or industry results expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially from anticipated results expressed or implied by forward-looking statements include, among others:
•our ability to obtain sufficient capital or strategic business arrangements to fund our operations and expansion plans, including collecting amounts owed to us under various licensing and other strategic arrangements, meeting our financial obligations under various licensing and other strategic arrangements, the funding of our clinical trials for product candidates, and the commercialization of the relevant technology;
•our ability to build and maintain the management and human resources infrastructure necessary to support the operation and/or growth of our business;
•whether a market is established for our products and our ability to capture a meaningful share of this market;
•scientific, regulatory and medical developments beyond our control;
•our ability to obtain and maintain, as applicable, appropriate governmental licenses, accreditations or certifications or to comply with healthcare laws and regulations or any other adverse effect or limitations caused by government regulation of our business;
•whether any of our current or future patent applications result in issued patents, the scope of those patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business, and our ability to commercialize products without infringing upon the claims of third-party patents;
•whether any potential strategic or financial benefits of various licensing agreements will be realized;
•our ability to diversify our pipeline of development product candidates, which could include an acquisition, merger, business combination, in-license or other strategic transaction, and whether any of such efforts will result in us entering into or completing any transaction or that any such transaction, if completed, will add to shareholder value;
•the results of our development activities;
•our ability to complete our other planned clinical trials (or initiate other trials) in accordance with our estimated timelines due to delays associated with enrolling patients due to the novelty of the treatment, the size of the patient population, competition with other clinical trials for similar subjects, patient and/or investigator site availability and accessibility due to external macroenvironmental factors and the need of patients to meet the inclusion criteria of the trial or otherwise;
•the extent to which any future public health crisis and their long-term effects may impact, directly or indirectly, our business, including our clinical trials and financial condition; and
•other factors discussed in “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 29, 2024 (our “2023 Form 10-K”).
The factors discussed herein, including those risks described in “Item 1A. Risk Factors” and elsewhere in our 2023 Form 10-K and in our other periodic filings with the SEC, which are available for review at www.sec.gov, could cause actual results and developments to be materially different from those expressed or implied by such statements. All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. Readers are cautioned not to place undue
2
reliance on these forward-looking statements, which speak only as of the date they were made. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

3
TABLE OF CONTENTS
PART I- FINANCIAL INFORMATION
Page No.
Item 1.
 
 
 
 
 
Notes to Unaudited Consolidated Financial Statements
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Item 4.
Controls and Procedures
PART II- OTHER INFORMATION
Item 1.
Legal Proceedings
Item 1A.
Risk Factors
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
Item 3.
Defaults Upon Senior Securities
Item 4.
Mine Safety Disclosures
Item 5.
Other Information
Item 6.
Exhibits
 
Signatures
4
PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS



LISATA THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
March 31,
2024		December 31,
2023
ASSETS(Unaudited)
Cash and cash equivalents$21,805 $22,593 
Marketable securities
21,544 27,942 
Prepaid and other current assets4,210 3,389 
Total current assets47,559 53,924 
Property and equipment, net146 175 
Acquired license - intangible, net245 263 
Other assets290 332 
Total assets$48,240 $54,694 
LIABILITIES, NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY  
Liabilities  
Accounts payable$1,263 $2,421 
Accrued liabilities4,070 4,169 
Total current liabilities5,333 6,590 
Other long-term liabilities164 210 
Total liabilities5,497 6,800 
Commitments and Contingencies (Note 13)
Stockholders' Equity 
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,308,171
and 8,150,635 shares at March 31, 2024 and December 31, 2023, respectively; and
outstanding, 8,307,433 and 8,149,897 shares at March 31, 2024 and December 31, 2023,
respectively
8 8 
Additional paid-in capital577,283 576,971 
Treasury stock, at cost; 738 shares at March 31, 2024 and December 31, 2023
(708)(708)
Accumulated deficit(533,482)(528,081)
Accumulated other comprehensive loss(104)(42)
Total Lisata Therapeutics, Inc. stockholders' equity42,997 48,148 
Non-controlling interests(254)(254)
Total equity42,743 47,894 
Total liabilities, non-controlling interests and stockholders' equity$48,240 $54,694 
See accompanying notes to consolidated financial statements.
5

LISATA THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
 (Unaudited)
(In thousands, except per share data)
 Three Months Ended March 31,
 20242023
Operating Expenses:
Research and development$3,241 $3,179 
General and administrative3,360 3,665 
Total operating expenses6,601 6,844 
Operating loss(6,601)(6,844)
Other income (expense):
Investment income, net589 670 
Other expense, net(187)(13)
Total other income 402 657 
     Net loss before benefit from income taxes and noncontrolling interests(6,199)(6,187)
Benefit from income taxes(798)— 
Net loss$(5,401)$(6,187)
Less - net income (loss) attributable to noncontrolling interests— — 
Net loss attributable to Lisata Therapeutics, Inc. common stockholders$(5,401)$(6,187)
Basic and diluted loss per share
Lisata Therapeutics, Inc. common stockholders$(0.65)$(0.77)
Weighted average common shares outstanding
Basic and diluted shares
8,294 7,987 

See accompanying notes to consolidated financial statements.
6
LISATA THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited) 
(In thousands)
 Three Months Ended March 31,
 20242023
Net loss$(5,401)$(6,187)
Other comprehensive loss:
Available for sale securities - net unrealized loss(13)(11)
Cumulative translation adjustment arising during the period(49)(12)
Total other comprehensive loss(62)(23)
Comprehensive loss attributable to Lisata Therapeutics, Inc. common
stockholders
$(5,463)$(6,210)
 
See accompanying notes to consolidated financial statements.
7
LISATA THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY
(Unaudited) 
(In thousands)
 Common StockAdditional
Paid-in
Capital		Accumulated
Other
Comprehensive
Loss		Accumulated
Deficit		Treasury
Stock		Total
Lisata Therapeutics,
Inc.
Stockholders'
Equity		Non-
Controlling
Interest in
Subsidiary		Total
Equity
 SharesAmount
Balance at December 31, 20227,867 $8 $574,548 $(29)$(507,241)$(708)$66,578 $(254)$66,324 
Net loss— — — — (6,187)— (6,187)— (6,187)
Share-based compensation132 — 589 — — — 589 — 589 
Unrealized loss on marketable securities— — — (11)— — (11)— (11)
Foreign currency translation adjustment— — — (12)— — (12)— (12)
Balance at March 31, 20237,999 $8 $575,137 $(52)$(513,428)$(708)$60,957 $(254)$60,703 
 Common StockAdditional
Paid-in
Capital		Accumulated
Other
Comprehensive Loss		Accumulated
Deficit		Treasury
Stock		Total
Lisata Therapeutics,
Inc.
Stockholders'
Equity		Non-
Controlling
Interest in
Subsidiary		Total
Equity
 SharesAmount
Balance at December 31, 20238,151 $8 $576,971 $(42)$(528,081)$(708)$48,148 $(254)$47,894 
Net loss— — — — (5,401)— (5,401)— (5,401)
Share-based compensation157 — 312 — — — 312 — 312 
Unrealized loss on marketable securities— — — (13)— — (13)— (13)
Foreign currency translation adjustment— — — (49)— — (49)— (49)
Balance at March 31, 20248,308 $8 $577,283 $(104)$(533,482)$(708)$42,997 $(254)$42,743 


See accompanying notes to consolidated financial statements.
 
8
LISATA THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
 
 Three Months Ended March 31,
 20242023
Cash flows from operating activities:  
Net loss$(5,401)$(6,187)
Adjustments to reconcile net loss to net cash used in operating activities:  
Share-based compensation454 675 
Depreciation and amortization46 48 
Loss on disposal of fixed assets— 3 
Loss from equity method investment100 — 
Amortization/accretion on marketable securities(152)(167)
Changes in operating assets and liabilities:  
Prepaid and other current assets(872)(1,652)
Other assets41 167 
Accounts payable, accrued liabilities and other liabilities(1,243)(1,083)
Net cash used in operating activities(7,027)(8,196)
Cash flows from investing activities:  
Purchase of marketable securities(18,824)(30,121)
Sale of marketable securities25,360 34,410 
Investment in Impilo Therapeutics(100)— 
Net cash provided by investing activities6,436 4,289 
Cash flows from financing activities:  
Tax withholding payments on net share settlement equity awards(142)(85)
Net cash used in financing activities(142)(85)
           Effect of exchange rate changes on cash(55)(7)
Net decrease in cash and cash equivalents(788)(3,999)
Cash and cash equivalents at beginning of period22,593 32,154 
Cash and cash equivalents at end of period$21,805 $28,155 
See accompanying notes to consolidated financial statements.
9
LISATA THERAPEUTICS, INC. AND SUBSIDIARIES
 
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Note 1 – The Business
Overview
Lisata Therapeutics, Inc. (together with its subsidiaries, the “Company”) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's lead investigational product candidate, certepetide (LSTA1), is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are expected to be unaffected. Certepetide also has been shown to modify the tumor microenvironment (“TME”), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). The Company and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics. To date, certepetide has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring certepetide as a means to enable a variety of treatment modalities to treat a range of solid tumors more effectively. Currently, certepetide, is the subject of several Phase 2 clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens.
The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. The Company's goal is to develop and commercialize products that address important unmet medical needs.
Basis of Presentation
The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of March 31, 2024, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2023 and 2022 included in our 2023 Form 10-K. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.
Principles of Consolidation
The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.


10
Foreign Currency Remeasurement
The Company’s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.
Note 2 – Summary of Significant Accounting Policies
Cash and Cash Equivalents
Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.
Concentration of Risks
The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.
Marketable Securities
The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.
Property and Equipment
The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:
Furniture and fixtures10 years
Computer equipment3 years
Software3 years
Leasehold improvementsLife of lease
Long-lived Assets
Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.
11
Share-Based Compensation  
The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.
Loss Per Share
Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.
Treasury Stock
Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.
Research and Development Costs 
Research and development (“R&D”) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.
To further drive the Company’s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.
In-process Research and Development Expense
Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a “business” as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.
Intangible Asset
The Company’s intangible asset consists of a single asset, a license agreement with Qilu Pharmaceutical, Co., Ltd. (“Qilu”) acquired in the Company's acquisition of Cend Therapeutics, Inc (the “Cend Merger”), with a value of $0.4 million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $17 thousand for the three months ended March 31, 2024 and $18 thousand for the three months ended March 31, 2023. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable. The projected amortization expense is $71 thousand per year for the next 3.5 years.



12
Revenue Recognition
The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.
If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three months ended March 31, 2024 and 2023.
Milestones
At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company’s collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company’s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March 31, 2024 and March 31, 2023, the Company has not recognized revenue related to milestones.
Royalties
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.
13
Note 3 – Available-for-Sale-Securities
The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):
March 31, 2024December 31, 2023
CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueCostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Corporate debt securities$33,750 $— $(18)$33,732 $37,791 $3 $(8)$37,786 
Commercial paper— — — — 1,981 — — 1,981 
Money market funds5,242 — — 5,242 4,268 — — 4,268 
Municipal debt securities247 — — 247 622 — — 622 
Total$39,239 $— $(18)$39,221 $44,662 $3 $(8)$44,657 


Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in the Company's Consolidated Balance Sheets (in thousands):
March 31, 2024December 31, 2023
Cash equivalents$17,677 $16,715 
Marketable securities21,544 27,942 
Total$39,221 $44,657 



The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):
March 31, 2024
Amortized CostEstimated Fair Value
Less than one year$39,239 $39,221 
Greater than one year— — 
Total$39,239 $39,221 


Note 4 – Property and Equipment
Property and equipment consisted of the following (in thousands):
March 31, 2024December 31, 2023
Computer equipment589 589 
Leasehold improvements72 72 
Property and equipment, gross661 661 
Accumulated depreciation(515)(486)
Property and equipment, net$146 $175 

The Company’s results included depreciation expense of approximately $29 thousand and $30 thousand for the three months ended March 31, 2024 and 2023, respectively.



14
Note 5 – Income (Loss) Per Share
For the three months ended March 31, 2024 and 2023, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive in the periods presented. At March 31, 2024 and 2023, the Company excluded the following potentially dilutive securities (in thousands):
 March 31
 20242023
Stock options1,454 1,493 
Warrants1,422 1,424 
Restricted stock units354 237 
 
Note 6 – Fair Value Measurements
Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:
Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.
Level 3 inputs are defined as unobservable inputs for the assets or liabilities.
Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.
The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 were as follows (in thousands):
March 31, 2024December 31, 2023
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Cash equivalents$17,677 $— $— $17,677 $16,715 $— $— $16,715 
Marketable securities - available for sale— 21,544 — 21,544 — 27,942 — 27,942 
$17,677 $21,544 $— $39,221 $16,715 $27,942 $— $44,657 

The carrying values of accounts payable and accrued expenses approximate fair value as of March 31, 2024 and December 31, 2023, due to the short maturity nature of these items.

15
Note 7 – Accrued Liabilities
Accrued liabilities as of March 31, 2024 and December 31, 2023 were as follows (in thousands):
March 31, 2024December 31, 2023
Salaries, employee benefits and related taxes$1,324 $2,665 
Clinical and R&D related liabilities1,724 1,046 
Accounting & tax consulting liabilities92 57 
Legal settlement500 — 
Operating lease liabilities — current172 168 
Other258 233 
Total$4,070 $4,169 

Note 8 – Operating Leases
The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.

16
Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):
March 31, 2024December 31, 2023
Right-of-Use Assets:
Other assets$267 $308 
Total Right-of-Use Asset$267 $308 
Operating Lease Liabilities:
Accrued liabilities$172 $168 
Other long-term liabilities92 137 
Total Operating Lease Liabilities$264 $305 
    
As of March 31, 2024, the weighted average remaining lease term for our operating lease was 1.5 years, and the weighted average discount rate for our operating lease was 9.625%. As of December 31, 2023, the weighted average remaining lease term for our operating leases was 1.75 years, and the weighted average discount rate for our operating leases was 9.625%.
Future minimum lease payments under the lease agreement as of March 31, 2024 were as follows (in thousands):
Years endedOperating Leases
2024143 
2025143 
Total lease payments286 
Less: Amounts representing interest(22)
Present value of lease liabilities$264 

Note 9 – Stockholders' Equity
Equity Issuances
At The Market Offering Agreement
On June 4, 2021, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC, as sales agent, in connection with an “at the market offering” under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0 million. As of the date of this filing and so long as the Company’s public float remains below $75.0 million, the Company is subject to limitations pursuant to General Instruction I.B.6 of Form S-3 (the “Baby Shelf Limitation”), which limits the amount the Company can offer to up to one-third of its public float during any trailing 12-month period. Subsequent to the filing of the Company's Registration Statement on Form S-3 (File No. 333-279034) on May 1, 2024, the aggregate market value of its outstanding common stock held by non-affiliates was approximately $26.7 million. Pursuant to the Baby Shelf Limitation, since the aggregate market value of the Company's outstanding common stock held by non-affiliates was below $75.0 million at the time of such S-3 filing, the aggregate amount of securities that the Company is permitted to offer and sell is now $8,915,094, which is equal to one-third of the aggregate market value of our common stock held by non-affiliates as of March 21, 2024. If the Company’s public float exceeds $75.0 million on a future measurement date, it will no longer be subject to the Baby Shelf Limitation. There were no issuances of common stock under the ATM Agreement for the three months ended March 31, 2024. Since inception, the Company has issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774.





17

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2024:
Stock OptionsWarrants
SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (In Thousands)SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 20231,322,501 $10.81 6.06$164.1 1,421,744 $42.51 2.42$— 
Changes during the period:
Granted132,575 3.07 — — 
Exercised— — — — 
Forfeited— — — — 
Expired(1,163)1,165.50 — — 
Outstanding at March 31, 20241,453,913 $9.18 6.18$232.1 1,421,744 $42.51 2.00$— 
Vested at March 31, 2024
or expected to vest in the future		1,443,689 $9.22 6.16$231.5 1,421,744 $42.51 2.00$— 
Vested at March 31, 20241,285,911 $9.92 5.75$215.9 1,421,744 $42.51 2.00$— 


Restricted Stock
During the three months ended March 31, 2024 and 2023, the Company issued restricted stock for services as follows (in thousands, except share data):
Three Months Ended March 31,
  20242023
Number of restricted stock issued203,800 159,950 
Value of restricted stock issued$628 $480 

The vesting terms of restricted stock issuances are generally between one and four years.

The following is a summary of the changes in non-vested restricted stock for the three months ended March 31, 2024:
Restricted Stock SharesWeighted Average Grant-Date Fair Value
Non-vested at December 31, 2023125,775 $5.86 
Changes during the Year:
Granted203,800 $3.08 
Vested(99,686)$5.22 
Forfeited— $— 
Non-vested at March 31, 2024229,889 $3.67 






18

Restricted Stock Units
During the three months ended March 31, 2024 and 2023, the Company issued restricted stock units for services as follows (in thousands, except share data):
Three Months Ended March 31,
20242023
Number of restricted stock units issued205,300 188,850 
Value of restricted stock units issued $632 $567 

The weighted average estimated fair value of restricted stock units issued for services in the three months ended March 31, 2024 and 2023 was $3.08 and $3.00 per share, respectively. The fair value of the restricted stock units was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.

The following is a summary of the changes in non-vested restricted stock units for the three months ended March 31, 2024:
Restricted Stock UnitsWeighted Average Grant-Date Fair Value
Non-vested at December 31, 2023112,800 $3.37 
Changes during the Year:
Granted97,400 $3.08 
Vested(100,000)$3.00 
Forfeited— $— 
Non-vested at March 31, 2024110,200 $3.45 

Note 10 – Share-Based Compensation
Share-Based Compensation
The Company utilizes share-based compensation in the form of stock options, restricted stock, and restricted stock units. The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
Research and development$86 $187 
General and administrative368 488 
Total share-based compensation expense$454 $675 

Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March 31, 2024 were as follows (in thousands):
Stock OptionsRestricted Stock UnitsRestricted Stock
Unrecognized compensation cost$371 $290 $751 
Expected weighted-average period in years of compensation cost to be recognized2.280.922.17





19
Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March 31, 2024 and 2023 were as follows (in thousands):
Stock Options
Three Months Ended March 31,
20242023
Total fair value of shares vested$199 $324 
Weighted average estimated fair value of shares granted$2.16 $0.78 

Valuation Assumptions
The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.

Note 11 – Income Taxes
In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.
As of December 31, 2023 and 2022, the Company had approximately $43.7 million and $33.7 million respectively, of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $88.2 million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in approximately $34.0 million of remaining Federal NOLs as of December 31, 2022. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations.
As of December 31, 2022, Cend Therapeutics, Inc. (“Cend”) had approximately $3.6 million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $3.1 million of Federal and $4.3 million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years. Using a fair market value of $36.1 million and applying an applicable federal rate of 2.54% Cend will have an annual limitation of approximately $917 thousand each year. The Federal NOL of $459 thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation and does not expire. As of December 31, 2023 and 2022, Cend’s wholly owned Australian subsidiary had approximately $2.4 million and $1.8 million, respectively, of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.
As of December 31, 2023, the Company had federal research and development credit carryforwards of $0.5 million expiring from 2027 through 2034 if unutilized, and state research and development credit carryforwards of $0.1 million, which carryforward indefinitely. Utilization of these credits may be subject to an annual limitation based on changes in ownership.
As of December 31, 2023 and 2022, the Company had State NOLs available in New Jersey of $19.4 million and $35.5 million, respectively, California of $9.2 million and $9.2 million, respectively, and New York City of $1.9 million and $1.9 million, respectively, to offset future taxable income expiring from 2032 through 2043. The usage of the Company’s NOLs is limited given the change in ownership.
The Company applies the FASB’s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.
As of December 31, 2023 and 2022, the Company’s uncertain tax positions were $344 thousand and $344 thousand, respectively. The uncertain tax positions are due to the acquisition of Cend related to Federal and state credits and certain state
20
NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.
For years prior to 2020, the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of three to four years from the date of the tax return filing.
On March 4, 2024, the Company received final approval from the New Jersey Economic Development Authority (“NJEDA”) under the Technology Business Tax Certificate Transfer Program (“Program”) to sell $8.9 million of its New Jersey net operating losses (“NJ NOLs”), which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $0.7 million. The sale of NJ NOLs resulted in a $0.8 million deferred income tax benefit and a loss on sale of $0.1 million recorded in other income (expense) in the consolidated financial statements.
On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for tax years beginning on or after January 1, 2023. For tax years beginning after December 31, 2021, the Tax Cuts & Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or 15 years beginning in 2022. Since the Company is in a net operating loss position, the capitalization of research and development costs did not have a material impact on the Company’s results of operations for the year ended December 31, 2023. The Company will continue to monitor the possible future impact of changes in tax legislation.

Note 12 – Australia Research and Development Tax Incentive

The Company’s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between 43.5% to 48.5% (depending upon the income tax rate) for qualified research and development activities. As of the three months ended March 31, 2024 and 2023, the Company had $1.0 million and $1.0 million, respectively, recorded as an income tax incentive receivable in prepaid and other current assets in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed.

Note 13 – Contingencies
Contingencies
From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. The Company has elected to recognize expense for legal fees as incurred when the legal services are provided.
In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (“Lingmed”) claiming Lingmed was entitled to a success fee based on Cend’s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend’s response to the complaint was filed on June 6, 2022 and denied all of Lingmed’s material allegations. Lingmed filed an answer to Cend’s response on July 11, 2022, denying all of the Company’s material allegations. On March 25, 2024 the Company entered into a settlement agreement whereby the Company is required to pay Lingmed $0.5 million within 30 days of the effective date and the Company effected payment on April 4, 2024. Lingmed is also entitled to 5.0% of any future milestone payments received by the Company under the license agreement with Qilu in addition to a sum of $250 thousand with respect to the first future milestone received by the Company. On April 9, 2024, pursuant to the parties’ joint request, the Court entered a dismissal with prejudice of the entire action as to all parties and all claims and the matter was settled.

Note 14 – Technology Transfer Agreement
Impilo Therapeutics
In July 2023, the Company entered into a technology transfer agreement with Impilo Therapeutics (“Impilo”) under which the Company transferred its rights to its tumor penetrating nanocomplex (TPN) platform to Impilo. As consideration for the technology transfer, Impilo issued a total of 766,000 shares of its pre-seed preferred stock to the Company. On October 3, 2023
21
in connection with the Sanford Burnham Prebys license agreement (Note 15) Impilo cancelled the original stock certificate for 766,000 shares and reissued 574,500 shares of its pre-seed preferred stock to the Company.
On March 15, 2024, the Company purchased a Simple Agreement for Future Equity ("SAFE") from Impilo for $100,000. As of March 31, 2024 and December 31, 2023 the Company owned 38.6% of Impilo. This investment was expensed under the equity method of accounting for the three months ended March 31, 2024 in other expense,net in the accompanying statement of operations. The SAFE has a valuation cap of $30.0 million and an 80% discount rate.
Note 15 – License Agreements
Sanford Burnham Prebys
In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (“SBP”) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of certepetide. At the time the license agreement was entered into, Cend’s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6 million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company’s pre-seed preferred stock in Impilo on October 3, 2023.
The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days’ prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.
SBP did not own shares of the Company’s common stock as of March 31, 2024.


Note 16 – Research Collaboration and License Agreement
Exclusive License and Collaboration Agreement
In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the “Qilu Agreement”) in which Cend granted an exclusive license to Qilu for the development and commercialization of certepetide in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of certepetide in its Territory. In consideration for the license, Qilu made an upfront payment of $10.0 million to Cend, which was recognized as revenue by Cend prior to the Company's acquisition of Cend on September 15, 2022 (the “Cend Merger”). In addition, Cend received and recognized as revenue a $5.0 million development milestone prior to the Cend Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $96.0 million and $125.0 million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.
On March 25, 2024 the Company entered into a settlement agreement with Lingmed whereby Lingmed is entitled to 5.0% of any future milestone payments received by the Company under the Qilu Agreement, in addition, Lingmed is also entitled to a sum of $250 thousand with respect to the first future milestone received by the Company.
Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined
22
period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate simultaneously.


Note 17 – Subsequent Events

On April 15, 2024, the Company’s Board of Directors appointed James Nisco as the Company’s Senior Vice President, Finance and Treasury and Chief Accounting Officer, effective immediately. Effective as of April 15, 2024, Mr. Nisco shall serve as the Company’s principal financial officer and principal accounting officer.
23
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Cautionary Note Regarding Forward-Looking Statements” herein and under “Risk Factors” in our 2023 Form 10-K. The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report and in our 2023 Form 10-K.
Overview
We are a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Our lead investigational product candidate, certepetide (LSTA1), is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are expected to be unaffected. Certepetide also has been shown to modify the tumor microenvironment (“TME”), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). We and our collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics. To date, certepetide has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. We are exploring certepetide as a means to enable a variety of treatment modalities to treat a range of solid tumors more effectively. Currently, certepetide, is the subject of several Phase 2 clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens.
Our leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Our goal is to develop and commercialize products that address important unmet medical needs.
Targeted Solid Tumor Penetration via CendR Active Transport
Many solid tumor cancers, including pancreatic ductal adenocarcinoma (“PDAC”), and cholangiocarcinoma, are surrounded by dense fibrotic tissue, or stroma. This stroma often limits the efficacy of current chemotherapies for these cancers. Emerging immunotherapies including but not limited to checkpoint inhibitors and adoptive cell therapies (e.g., chimeric antigen receptor T cells (CAR-Ts)) also face challenges in penetrating solid tumors. Many tumors also exhibit an immunosuppressive TME, which suppresses patients’ immune systems and can thus limit the effectiveness of immunotherapies and/or contribute to metastases. These factors negatively impact the ability of many therapeutic agents to effectively treat these cancers.
To address the tumor stroma’s role as a primary impediment to effective treatment, our approach is to activate the C-end rule (“CendR”), or CendR system, a naturally occurring active transport system. Our lead investigational drug, certepetide (a specific internalizing R-G-D or iRGD peptide), activates this transport system in a tumor-specific manner (Sugahara, Science, 2010). Certepetide enables more selective and efficient uptake of systemically administered anti-cancer drugs resulting in more intratumoral drug accumulation. The overall expected result is enhanced anticancer activity without an increase in adverse side effects. While it is possible to couple/tether or conjugate some anticancer drugs to certepetide, we believe that the co-administration of certepetide with anti-cancer therapies is advantageous. Co-administration does not create a new chemical entity with its attendant development and regulatory hurdles, thereby providing an anticipated faster-to-clinic and faster-to-market product opportunity for a range of co-administration therapies.
Certepetide has demonstrated favorable safety, tolerability, and activity to date in clinical trials enhancing the delivery of standard-of-care chemotherapies for mPDAC. Certepetide’s cancer-targeted delivery may enable such emerging treatment modalities to treat a range of solid tumors potentially more effectively.
Certepetide as a treatment for solid tumor cancers in combination with other anti-cancer agents
Certepetide is an investigational drug that actuates the CendR active transport mechanism. Certepetide has been shown to modify the TME, making it less immunosuppressive and thereby making the tumor more susceptible to attack by the immune system while also inhibiting the metastasis cascade. It targets tumor vasculature, endothelial cells, tumor cells and some intratumoral immunosuppressive cells by its selective affinity for alpha-v beta-3 and beta-5 integrins that are upregulated on these cells. Certepetide is a nine amino acid cyclic internalizing RGD (“iRGD”) peptide that, once bound to these integrins, is
24
cleaved by proteases expressed in tumors to release a linear peptide fragment, called a CendR peptide fragment. The CendR peptide fragment then binds to an adjacent receptor, called neuropilin-1, also upregulated in solid tumors, to activate a novel uptake pathway that allows circulating anticancer drugs to more selectively and effectively penetrate solid tumors. The ability of certepetide and iRGD peptides to modify the TME to enhance delivery and efficacy of co-administered drugs has been demonstrated in many preclinical models in a range of solid tumors. Lisata, its collaborators, and research groups around the world have published over 350 related scientific papers in this regard.
Clinically, certepetide was the subject of a completed Phase 1b/2a trial inclusive of 31 first-line mPDAC patients, of which 29 were evaluable. Results from the trial showed that the safety profile of the certepetide combination regimen was similar to standard of care (“SoC”) alone with certepetide being well-tolerated with no-dose limiting toxicities. An Objective Response Rate (“ORR”) of 59% was observed, compared to the 23% ORR observed in the “MPACT” clinical trial that served as the basis for approval of nab-paclitaxel for use in combination with gemcitabine for the treatment of first line, mPDAC (Von Hoff, et al. 2013). A Disease Control Rate (“DCR”) (partial and complete responses plus stable disease) of over 79% was also observed in comparison to a DCR of 48% observed in the MPACT trial. Reduction in the level of circulating tumor biomarker CA19-9 was observed in 96% of patients versus 61% in the MPACT trial. Importantly, median progression-free survival and median overall survival of nearly ten months and over thirteen months were observed versus less than six months and less than nine months, respectively, in the MPACT trial. These results have been published in The Lancet Gastroenterology and Hepatology (Dean, et al. 2022).
Additionally, certepetide is currently the subject of multiple ongoing and planned clinical trials being conducted globally in a variety of solid tumor types and in combination with several chemotherapy and immunotherapy anti-cancer regimens. The following diagram summarizes these studies.
Slide1.jpg








25
Slide2.jpg



Additional Out-licensing Opportunities
Our broad intellectual property portfolio of assets includes notable programs available for out-licensing in order to augment or continue their clinical development. Our current long-term strategy focuses on advancing our therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. We believe that we are well-positioned to realize potentially meaningful value increases within our own proprietary pipeline if we are successful in advancing our product candidates to their next significant development milestones.












26
Results of Operations
Three Months Ended March 31, 2024 Compared to Three Months Ended March 31, 2023
The following table summarizes our results of operations for the three months ended March 31, 2024 and March 31, 2023 (in thousands):
 Three Months Ended March 31,
 20242023Change
Operating Expenses:
  Research and development$3,241 $3,179 $62 
  General and administrative3,360 3,665 (305)
     Total operating expenses6,601 6,844 (243)
  Loss from operations(6,601)(6,844)243 
Total other income402 657 (255)
Benefit from income taxes(798)— 798 
  Net loss$(5,401)$(6,187)$786 
 Overall, net losses were $5.4 million for the three months ended March 31, 2024, compared to $6.2 million for the three months ended March 31, 2023.
Operating Expenses
For the three months ended March 31, 2024, operating expenses totaled $6.6 million, compared to $6.8 million for the three months ended March 31, 2023, representing a decrease of $0.2 million or 3.6%. Operating expenses comprised the following: 
•Research and development expenses were approximately $3.2 million for the three months ended March 31, 2024, compared to $3.2 million for the three months ended March 31, 2023, representing an increase of $62.0 thousand or 2.0%. This was primarily due to an increase in expenses associated with our enrollment activities in the current year for our certepetide Phase 2a proof-of-concept Bolster trial partially offset by a reduction in expenses associated with the Phase 2b ASCEND trial which completed enrollment in the prior year.
•General and administrative expenses were approximately $3.4 million for the three months ended March 31, 2024, compared to $3.7 million for the three months ended March 31, 2023, representing a decrease of $0.3 million or 8.3%. This was primarily due to a decrease in staffing costs associated with the elimination of the Chief Business Officer position on May 1, 2023, a reduction in option assumption equity expense in connection with the Cend Merger, a decrease in directors and officers insurance premiums, and a reduction in spend on consulting and legal fees partially offset by one-off settlement related costs.
Historically, to minimize our use of cash, we have used a variety of equity instruments to compensate employees, consultants and other service providers. The use of these instruments has resulted in charges to the results of operations, which have been significant in the past.
Other Income (Expense)
Total other income (expense) is comprised primarily of investment income from cash, cash equivalents and marketable securities for the three months ended March 31, 2024 and 2023, with the current year period also including a loss on sale related to the sale of our New Jersey net operating losses (“NJ NOLs”) and an investment in Impilo Therapeutics, Inc which was fully expensed under the equity method of accounting.
Income Tax Benefit
In March 2024, we received final approval from the New Jersey Economic Development Authority (“NJEDA”) under the Technology Business Tax Certificate Transfer Program (the “Program”) to sell a percentage of our NJ NOLs, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $0.7 million. The $0.8
27
million of our NJ NOL tax benefits have been recorded as a benefit from income taxes and the loss on sale of $0.1 million recorded in other income (expense).


28
Analysis of Liquidity and Capital Resources
As of March 31, 2024, we had cash, cash equivalents and marketable securities of approximately $43.3 million, working capital of approximately $42.2 million, and stockholders’ equity of approximately $43.0 million.
During the three months ended March 31, 2024, we met our immediate cash requirements through existing cash balances. Additionally, we used equity and equity-linked instruments to pay for services and compensation.
Net cash (used in) or provided by, operating, investing and financing activities were as follows (in thousands): 
 Three Months Ended March 31,
 20242023
Net cash used in operating activities$(7,027)$(8,196)
Net cash provided by investing activities6,436 4,289 
Net cash used in financing activities(142)(85)
 
Operating Activities
Our cash used in operating activities during the three months ended March 31, 2024 was $7.0 million, which is comprised of (i) our net loss of $5.4 million, adjusted for non-cash expenses totaling $0.4 million (which includes adjustments for equity-based compensation, depreciation and amortization, loss from equity method investment, and amortization/accretion of marketable securities), and (ii) changes in operating assets and liabilities using approximately $2.1 million.
Our cash used in operating activities during the three months ended March 31, 2023 was $8.2 million, which is comprised of (i) our net loss of $6.2 million, adjusted for non-cash expenses totaling $0.6 million (which includes adjustments for equity-based compensation, depreciation and amortization, a loss on disposal of fixed assets, and amortization/accretion of marketable securities) and (ii) changes in operating assets and liabilities using approximately $2.6 million.
Investing Activities
Our cash provided by investing activities during the three months ended March 31, 2024 totaled $6.4 million and was primarily due to net sales of marketable securities (net of purchases of marketable securities) partially offset by an investment of $0.1 million in Impilo Therapeutics.
Our cash provided by investing activities during the three months ended March 31, 2023 totaled $4.3 million and was primarily due to net sales of marketable securities (net of purchases of marketable securities).
Financing Activities
Our cash used in financing activities during the three months ended March 31, 2024 totaled $0.1 million and consisted of tax withholding-related payments on net share settlement equity awards to employees.
Our cash used in financing activities during the three months ended March 31, 2023 totaled $0.1 million and consisted of tax withholding-related payments on net share settlement equity awards to employees.
Liquidity and Capital Requirements Outlook
To meet our short and long-term liquidity needs, we expect to use existing cash balances, marketable securities and a variety of other means. Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, partnerships and/or collaborations and/or sale of assets. Our history of operating losses and liquidity challenges may make it difficult for us to raise capital on acceptable terms or at all. The demand for the equity and debt of pharmaceutical companies like ours is dependent upon many factors, including the general state of the financial markets. During times of extreme market volatility, capital may not be available on favorable terms, if at all. Our inability to obtain such additional capital could materially and adversely affect our business operations. We will also continue to seek, as appropriate, grants for scientific and clinical studies from various governmental agencies and foundations, and other sources of non-dilutive funding. We believe that our cash on hand and marketable securities will enable us to fund operating expenses for at least the next 12 months following the issuance of our financial statements. Our future capital requirements are difficult to forecast and will depend on many factors including the timing and nature of any other strategic transactions that we undertake; and our ability to establish and maintain collaboration partnerships, in-license/out-license or other similar arrangements and the financial terms of such agreements.

29
On June 4, 2021, we entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC as sales agent, in connection with an “at the market offering” under which we from time to time may offer and sell shares of our common stock having an aggregate offering price of up to $50.0 million. As of the date of this filing and so long as our public float remains below $75.0 million, we are subject to limitations pursuant to General Instruction I.B.6 of Form S-3 (the “Baby Shelf Limitation”), which limits the amount we can offer to up to one-third of our public float during any trailing 12-month period. Subsequent to the filing of our Registration Statement on Form S-3 (File No. 333-279034) on May 1, 2024, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $26.7 million. Pursuant to the Baby Shelf Limitation, since the aggregate market value of our outstanding common stock held by non-affiliates was below $75.0 million at the time of such S-3 filing, the aggregate amount of securities that we are permitted to offer and sell is now $8,915,094, which was equal to one-third of the aggregate market value of our common stock held by non-affiliates as of March 21, 2024. If our public float exceeds $75.0 million on a future measurement date, the Company will no longer be subject to the Baby Shelf Limitation. There were no issuances of common stock under the ATM Agreement for the three months ended March 31, 2024. Since inception we have issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774.
While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and our negotiating position in capital generating efforts may worsen as existing resources are used. Additional equity financing may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict our ability to operate as a business; our stock price may not reach levels necessary to induce option or warrant exercises; and asset sales may not be possible on terms we consider acceptable. If we are unable to access capital necessary to meet our long-term liquidity needs, we may have to delay the expansion of our business or raise funds on terms that we currently consider unfavorable.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements.
Critical Accounting Policies and Estimates
There have been no material changes in our critical accounting policies and estimates during the three months ended March 31, 2024, compared to those reported in our 2023 Form 10-K.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
ITEM 4.  CONTROLS AND PROCEDURES
(a)  Disclosure Controls and Procedures
Disclosure controls and procedures are our controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), as amended (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer, who serves as our principal executive officer and who served as our principal financial officer for the three months ended March 31,2024, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well-designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.
As of March 31, 2024, we evaluated, with the participation of our management, including our Chief Executive Officer, the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our Chief Executive Officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules
30
and forms and is accumulated and communicated to management, including the Chief Executive Officer, as appropriate to allow timely decisions regarding required disclosure.
(b)  Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15, that occurred during our last quarter to which this Quarterly Report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Subsequent to March 31, 2024, the Company’s Board of Directors appointed James Nisco as the Company’s Senior Vice President, Finance and Treasury and Chief Accounting Officer, effective immediately, and Mr. Nisco simultaneously began serving as our principal financial officer and principal accounting officer.
31
PART II

OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS
Other than as disclosed in “Note 13 – Contingencies” set forth in the Notes to Unaudited Consolidated Financial Statements, which are included herein, there are no material changes to the disclosures previously reported in our 2023 Form 10-K.
ITEM 1A. RISK FACTORS
There have been no material changes to the risk factors previously reported in our 2023 Form 10-K. See the risk factors set forth in our 2023 Annual Report on Form 10-K under the caption “Item 1A - Risk Factors.”

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES
None.

ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.

ITEM 5. OTHER INFORMATION
During the three months ended March 31, 2024, no director or officer of the Company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

ITEM 6. EXHIBITS
The Exhibit Index appearing immediately after the signature page to this Form 10-Q is incorporated herein by reference.
32
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
   
  LISATA THERAPEUTICS, INC.
May 9, 2024 
By: /s/ David J. Mazzo, PhD
Name: David J. Mazzo, PhD
Title: President & Chief Executive Officer
(Principal Executive Officer)
May 9, 2024
By: /s/ James Nisco
Name: James Nisco
Title: SVP, Finance and Treasury and Chief Accounting Officer (Principal Financial Officer and Principal Accounting Officer)





33
LISATA THERAPEUTICS, INC.
FORM 10-Q

Exhibit Index
*Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
*Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
**Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
**Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INSInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCHInline XBRL Taxonomy Extension Schema
101.CALInline XBRL Taxonomy Extension Calculation Linkbase
101.DEFInline XBRL Taxonomy Extension Definition Linkbase
101.LABInline XBRL Taxonomy Extension Label Linkbase
101.PREInline XBRL Taxonomy Extension Presentation Linkbase
104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
_______________
*Filed herewith.
**Furnished herewith.
34
EX-31.1 2 lsta-ex311_20240331.htm EX-31.1 Document

Exhibit 31.1
 
CERTIFICATIONS UNDER SECTION 302
 
I, David J. Mazzo, PhD, certify that:
 
1.  I have reviewed this Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc.;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.  The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
 
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.  The registrant's other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: May 9, 2024

/s/ David J. Mazzo, PhD    
Name: David J. Mazzo, PhD
Title: President & Chief Executive Officer
(Principal Executive Officer)

 EX-31.2 3 lsta-ex312_20240331.htm EX-31.2 Document

Exhibit 31.2
 
CERTIFICATIONS UNDER SECTION 302
 
I, James Nisco, certify that:
 
1.  I have reviewed this Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc.;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.  The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
 
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.  The registrant's other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: May 9, 2024

/s/ James Nisco    
Name: James Nisco
Title: Senior Vice President, Finance and Treasury and Chief Accounting Officer
(Principal Financial Officer and Principal Accounting Officer)

 EX-32.1 4 lsta-ex321_20240331.htm EX-32.1 Document

Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc. (the “Company”) for the quarter ended March 31, 2024 filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David J. Mazzo, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:
 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.
 
Dated:  May 9, 2024
 
 /s/ David J. Mazzo, PhD
 David J. Mazzo, PhD
 President & Chief Executive Officer (Principal Executive Officer)
 
The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.
 



 EX-32.2 5 lsta-ex322_20240331.htm EX-32.2 Document

Exhibit 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc. (the “Company”) for the quarter ended March 31, 2024 filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James Nisco, Senior Vice President, Finance and Treasury and Chief Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:
 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.
 
Dated:  May 9, 2024
 
 /s/ James Nisco
 James Nisco
 Senior Vice President, Finance and Treasury and Chief Accounting Officer (Principal Financial Officer and Principal Accounting Officer)
 
The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.
 



 EX-101.SCH 6 lsta-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - The Business link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Available-for-Sale-Securities link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Operating Leases link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Australia Research and Development Tax Incentive link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Technology Transfer Agreement link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - License Agreements link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Research Collaboration and License Agreement link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Available-for-Sale-Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Operating Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Income (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Operating Leases - Balance Sheet Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Operating Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Stockholders' Equity - Equity Issuances (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Stockholders' Equity - Stock Options and Warrants Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Australia Research and Development Tax Incentive (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Technology Transfer Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - License Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Research Collaboration and License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 lsta-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 lsta-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 lsta-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Percentage held by non-affiliates Sale of Stock Available for Sale, Percentage Sale of Stock Available for Sale, Percentage Pay vs Performance Disclosure [Line Items] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Accrued liabilities Total Accrued Liabilities, Current Statistical Measurement [Domain] Statistical Measurement [Domain] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Warrants, Vested and expected to vest (in shares) shares, vested and expected to vest shares, vested and expected to vest Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Available-for-sale Securities Reconciliation Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Long-lived Assets Property, Plant and Equipment, Impairment [Policy Text Block] Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Computer equipment Computer Equipment [Member] Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] Corporate debt securities Corporate Debt Securities [Member] Total other income Nonoperating Income (Expense) Commitments and Contingencies (Note 13) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Stockholders' Equity Equity [Text Block] Options, Vested and expected to vest, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Net proceeds from issuance of common stock Proceeds from Issuance of Common Stock Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Option to terminate Research Collaboration and License Agreement, Option to Terminate Research Collaboration and License Agreement, Option to Terminate Income Taxes Income Tax Disclosure [Text Block] Warrants, Vested, Weighted Average Exercise Price (in dollars per share) Weighted Average Exercise Price, Warrants Exercisable Weighted Average Exercise Price, Warrants Exercisable Leases Lessee, Leases [Policy Text Block] Income Tax Holiday [Line Items] Income Tax Holiday [Line Items] Weighted-Average Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share) Earnings Per Share, Diluted Schedule of Investments [Table] Schedule of Investments [Table] PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Options, Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Treasury stock (in shares) Treasury Stock, Common, Shares Options, Outstanding, Beginning of Period (in shares) Options, Outstanding, End of Period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Litigation Case [Axis] Litigation Case [Axis] Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Options, Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Marketable securities - available for sale Investments, Fair Value Disclosure Sublicensing fee Collaborative Arrangement, Rights and Obligations, Sublicensing Fees Collaborative Arrangement, Rights and Obligations, Sublicensing Fees Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Weighted average estimated fair value of shares granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net loss attributable to Lisata Therapeutics, Inc. common stockholders Net Income (Loss) Attributable to Parent Net Income (Loss) Total current liabilities Liabilities, Current Shares canceled (in shares) Investment Owned, Canceled, Shares Investment Owned, Canceled, Shares Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Foreign Currency Remeasurement Foreign Currency Transactions and Translations Policy [Policy Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name SAFE, discount rate SAFE, Discount Rate SAFE, Discount Rate Operating Leases Lessee, Operating Leases [Text Block] Warrants, Weighted Average Exercise Price, Vested or expected to vest in the future (in dollars per share) Weighted Average Exercise Price, Warrants Vested And Expected To Vest Weighted Average Exercise Price, Warrants Vested And Expected To Vest LIABILITIES, NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Warrants, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term warrant outstanding Weighted Average Remaining Contractual Term warrant outstanding Stockholders' Equity Equity, Attributable to Parent [Abstract] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Contract with customer, liability Contract with Customer, Liability Options, Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Annual license maintenance fee Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Vesting term Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Executive Category: Executive Category [Axis] Schedule of Total Compensation Cost Related to Nonvested Awards Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Warrants, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Options, Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Statement, Equity Components [Axis] Equity Components [Axis] Research Tax Credit Carryforward Research Tax Credit Carryforward [Member] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Less than one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Available for sale securities - net unrealized loss OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Measurement Frequency [Axis] Measurement Frequency [Axis] Warrants Warrant [Member] Other long-term liabilities Operating Lease, Liability, Noncurrent Investments Classified by Contractual Maturity Date Investments Classified by Contractual Maturity Date [Table Text Block] Restricted stock units Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Depreciation Depreciation Schedule of Marketable Securities Marketable Securities [Table Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Research tax credit rate Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Research and development Research and Development Expense (Excluding Acquired in Process Cost) Technology Transfer Agreement [Abstract] Technology Transfer Agreement Schedule of Future Minimum Lease Payments Under Lease Agreements Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Potential milestone payments Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Product and Service [Domain] Product and Service [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Research and development Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Total fair value of shares vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Award Type [Axis] Award Type [Axis] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Revenue from collaborative arrangement Revenue from contract Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Shares held by third party (in shares) Shares Held by Third Party Shares Held by Third Party Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] General and administrative General and Administrative Expense [Member] Property and equipment, gross Property, Plant and Equipment, Gross Options, Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Income tax incentive receivable Income Tax Incentive Receivable Income Tax Incentive Receivable Expected amortization, remainder of fiscal year Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Trading Arrangement: Trading Arrangement [Axis] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Less: Amounts representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Debt Securities, Available-for-sale [Abstract] Debt Securities, Available-for-Sale [Abstract] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Operating lease liabilities — current Accrued liabilities Operating Lease, Liability, Current License License [Member] California California Franchise Tax Board [Member] Warrants, Granted (in shares) Warrants Granted Warrants Granted Software Computer Software, Intangible Asset [Member] Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Acquired license - intangible, net Finite-Lived Intangible Assets, Net Restatement Determination Date Restatement Determination Date Warrants Outstanding, Beginning of Period (in dollars per share) Warrants Outstanding, End of Period (in dollars per share) Weighted Average Exercise Price, Warrants Outstanding Weighted Average Exercise Price, Warrants Outstanding Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Common stock, shares issued (in shares) Common Stock, Shares, Issued Schedule of Restricted Stock Units Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Schedule of Fair Value of Share-based Compensation Awards Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Treasury stock, at cost; 738 shares at March 31, 2024 and December 31, 2023 Treasury Stock, Common, Value Security Exchange Name Security Exchange Name Assets, fair value disclosure Assets, Fair Value Disclosure Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] General and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax License Agreements Research Collaboration and License Agreement Collaborative Arrangement Disclosure [Text Block] Stock options Employee Stock Option [Member] Right-of-Use Assets: Operating Lease, Right-Of-Use Asset [Abstract] Operating Lease, Right-Of-Use Asset Expected weighted-average period in years of compensation cost to be recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Maximum Maximum [Member] Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Cash equivalents Cash Equivalents, at Carrying Value Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Federal Domestic Tax Authority [Member] Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest Entity Address, Address Line One Entity Address, Address Line One Operating loss carryforwards subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Exclusive License and Collaboration Agreement Exclusive License and Collaboration Agreement [Member] Exclusive License and Collaboration Agreement Share-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Stock Options, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Operating loss carryforwards, post acquisition Operating Loss Carryforwards, Post Acquisition Operating Loss Carryforwards, Post Acquisition Subsequent event Subsequent Event [Member] Net operating loss carryforwards Operating Loss Carryforwards Investment owned (in shares) Investment Owned, Balance, Shares Warrants Outstanding, Aggregate Intrinsic Value Aggregate Intrinsic Value, Warrants Outstanding Aggregate Intrinsic Value, Warrants Outstanding Income Statement [Abstract] Income Statement [Abstract] Stock issued (in shares) Stock Issued During Period, Shares, New Issues Options, Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Treasury Stock Stockholders' Equity, Policy [Policy Text Block] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Beginning balance, Weighted average grant date fair value (in dollars per share) Ending balance, Weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] ATM Agreement At The Market Offering Agreement [Member] At The Market Offering Agreement Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Stock Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Purchase of marketable securities Payments to Acquire Marketable Securities Warrants, Outstanding, Beginning of Period (in shares) Warrants, Outstanding, End of Period (in shares) Common Stock Warrants, Shares Common Stock Warrants, Shares Statistical Measurement [Axis] Statistical Measurement [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Schedule of Available-for-sale Securities [Table] Debt Securities, Available-for-Sale [Table] Total Shareholder Return Amount Total Shareholder Return Amount Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Litigation settlement, first milestone payment Litigation Settlement, Milestone Payment Litigation Settlement, Milestone Payment Greater than one year Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Total Lisata Therapeutics, Inc. Stockholders' Equity Parent [Member] NOL annual limitation Net Carryforward Operating Loss Carryforward Annual Limitation Net Carryforward Operating Loss Carryforward Annual Limitation Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Number of shares issued (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Leases [Abstract] Leases [Abstract] Basic and diluted loss per share EPS [Abstract] EPS Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Income Tax Holiday [Table] Income Tax Holiday [Table] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Warrants, Weighted Average Contractual Term and Intrinsic Value Warrants Other Disclosures [Abstract] Warrants Other Disclosures Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Expected amortization, year one Finite-Lived Intangible Asset, Expected Amortization, Year One Unrealized loss on marketable securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock outstanding (in shares) Common stock, beginning balance (in shares) Common stock, ending balance (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] Concentration of Risks Concentration Risk, Credit Risk, Policy [Policy Text Block] Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Greater than one year Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value Stock Options, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Technology Transfer Agreement Technology Transfer Agreement [Text Block] Technology Transfer Agreement Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective income tax rate reconciliation Effective Income Tax Rate Reconciliation, Percent Total Operating Lease Liabilities Present value of lease liabilities Operating Lease, Liability Options, Vested, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Total liabilities Liabilities New York New York State Division of Taxation and Finance [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Options, Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Prepaid and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Total Cash, Cash Equivalents, and Short-Term Investments Measurement Frequency [Domain] Measurement Frequency [Domain] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] All Executive Categories All Executive Categories [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Litigation settlement, future milestone payments Litigation Settlement, Future Milestone Payments, Percent Litigation Settlement, Future Milestone Payments, Percent Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Shares issued under license agreement (in shares) Shares Issued Under License Agreement Shares Issued Under License Agreement Earnings Per Share [Abstract] Earnings Per Share [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Sale of stock available for sale Sale of Stock Available for Sale Sale of Stock Available for Sale Research and Development Costs Research, Development, and Computer Software, Policy [Policy Text Block] Marketable Securities Marketable Securities, Policy [Policy Text Block] Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,308,171 and 8,150,635 shares at March 31, 2024 and December 31, 2023, respectively; and outstanding, 8,307,433 and 8,149,897 shares at March 31, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Operating lease liabilities, noncurrent, balance sheet line item Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Total current assets Assets, Current Annual license maintenance fee, year seven Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven Investment income, net Investment Income, Net SAFE, valuation cap SAFE, Valuation Cap SAFE, Valuation Cap Loss on sale of NOL Loss On Sale of NOL Loss On Sale of NOL Proceeds from sale of NOLs, gross Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross Share-based compensation Issuance of Stock and Warrants for Services or Claims All Individuals All Individuals [Member] Litigation Case [Domain] Litigation Case [Domain] Other expense, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Warrants, Exercised (in dollars per share) Weighted Average Exercise Price, Warrants Exercised Weighted Average Exercise Price, Warrants Exercised Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Loss Per Share Earnings Per Share, Policy [Policy Text Block] Unrecognized tax benefits Unrecognized Tax Benefits Available-for-Sale-Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Income Tax Authority [Axis] Income Tax Authority [Axis] PEO Name PEO Name Options, Vested, Weighted Average Remaining Contractual Term Options, Vested, weighted Average Remaining Contractual Term Options, Vested, weighted Average Remaining Contractual Term Warrants, Expired (in shares) Warrants Expired Warrants Expired Weighted average estimated fair value (in dollars per share) Granted, Weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Warrants, Exercised (in shares) Warrants Exercised Warrants Exercised Options, Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Impilo Impilo [Member] Impilo Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Other Other Accrued Liabilities, Current Investment in Impilo Therapeutics Payments to acquire Impilo SAFE Payments to Acquire Other Investments Litigation settlement, amount awarded to other party Litigation Settlement, Amount Awarded to Other Party Furniture and fixtures Furniture and Fixtures [Member] Royalties, net of sales Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total Lisata Therapeutics, Inc. stockholders' equity Equity, Attributable to Parent Commercial paper Commercial Paper [Member] Warrants, Vested (in shares) Warrants, Vested Warrants, Vested Restricted Stock Restricted Stock [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Finance Minimum Lease Payments Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Lingmed Limited Lingmed Limited [Member] Lingmed Limited Cumulative translation adjustment arising during the period Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Subsequent Events [Abstract] Subsequent Events [Abstract] Net loss before benefit from income taxes and noncontrolling interests Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest The Business The Business [Text Block] The Business [Text Block] Municipal debt securities US States and Political Subdivisions Debt Securities [Member] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Level 2 Fair Value, Inputs, Level 2 [Member] Warrants, Vested, Weighted Average Remaining Contractual Term weighted Average Remaining Contractual Term, warrants vested weighted Average Remaining Contractual Term, warrants vested Entity Emerging Growth Company Entity Emerging Growth Company Estimated Fair Value Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) New Jersey New Jersey Division of Taxation [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Less - net income (loss) attributable to noncontrolling interests Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest Document Fiscal Period Focus Document Fiscal Period Focus Litigation settlement, payment term Litigation Settlement, Payment Term Litigation Settlement, Payment Term 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Title Trading Arrangement, Individual Title Options, Outstanding. Beginning of Period (in dollars per share) Options, Outstanding, End of Period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Common Stock Common Stock [Member] Foreign Tax Authority Foreign Tax Authority [Member] Options, Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Income (Loss) Per Share Earnings Per Share [Text Block] Total share-based compensation expense Income Statement Location [Domain] Royalty Royalty [Member] Ownership percentage Equity Method Investment, Ownership Percentage Document Fiscal Year Focus Document Fiscal Year Focus Warrants Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest CEND CEND [Member] CEND Minimum Minimum [Member] Weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Schedule of Stock Option and Warrants Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Total other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Warrants, Expired (in dollars per share) Weighted Average Exercise Price, Warrants Expired Weighted Average Exercise Price, Warrants Expired Tax withholding payments on net share settlement equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Liabilities Liabilities [Abstract] Right-of-use assets, balance sheet line item Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Schedule of Assets Measured at Fair Value on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Contingencies Commitments and Contingencies Disclosure [Text Block] Warrants, Forfeited (in shares) Warrants Canceled Warrants Canceled Percentage of sublicensing revenues Revenue, Performance Obligation, Percentage of Sublicensing Revenues Revenue, Performance Obligation, Percentage of Sublicensing Revenues Accumulated Deficit Retained Earnings [Member] Less than one year Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year Legal settlement Legal Settlement, Current Legal Settlement, Current Schedule Share-based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Amortization/accretion on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities, non-controlling interests and stockholders' equity Liabilities and Equity Cost Debt Securities, Available-for-Sale, Amortized Cost Other income (expense): Nonoperating Income (Expense) [Abstract] Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Percentage of net sale Revenue, Performance Obligation, Percentage of Net Sale Revenue, Performance Obligation, Percentage of Net Sale Right-of-use assets Operating Lease, Right-of-Use Asset Lisata Therapeutics, Inc. common stockholders- basic (in usd per share) Earnings Per Share, Basic Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Sale of Stock, Name of Transaction [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Options, Vested and expected to vest, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Options, Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Principles of Consolidation Consolidation, Policy [Policy Text Block] Investments in and Advances to Affiliates [Line Items] Investments in and Advances to Affiliates [Line Items] Operating lease liabilities, current, balance sheet line item Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Variable consideration amounts, milestones Revenue, Remaining Performance Obligation, Variable Consideration Amount Revenue, Remaining Performance Obligation, Variable Consideration Amount Termination Date Trading Arrangement Termination Date Fair value market of tax NOLs Fair Value Market of Tax NOLs Fair Value Market of Tax NOLs Sale of marketable securities Proceeds from Sale and Maturity of Marketable Securities Common stock, shares authorized (in shares) Common Stock, Shares Authorized Estimated Fair Value Total Debt Securities, Available-for-Sale Aggregate offering amount authorized per agreement Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement Accrued Liabilities [Abstract] Accrued Liabilities [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Accounts payable, accrued liabilities and other liabilities Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities Outstanding stock threshold Outstanding Stock Threshold Outstanding Stock Threshold Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Net operating loss carryforwards, prior to write down Operating Loss Carryforwards, Before Write Down Operating Loss Carryforwards, Before Write Down All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Common stock, value, outstanding Common Stock, Value, Outstanding Award Timing Disclosures [Line Items] Warrants, Weighted Average Exercise Price Warrants Weighted Average Exercise Price [Roll Forward] Warrants Weighted Average Exercise Price [Roll Forward] Compensation Amount Outstanding Recovery Compensation Amount Additional paid-in capital Additional Paid in Capital Forfeited, Weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Value of shares issued Stock Issued During Period, Value, Restricted Stock Award, Gross Subsequent Event Type [Axis] Subsequent Event Type [Axis] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Milestones, Royalties Collaborative Arrangement, Accounting Policy [Policy Text Block] Options, Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid and other current assets Prepaid Expense and Other Assets, Current Expected amortization, year three Finite-Lived Intangible Asset, Expected Amortization, Year Three Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Accounting & tax consulting liabilities Accrued Grant Funding Accrued Grant Funding Insider Trading Arrangements [Line Items] Options, Outstanding, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-based compensation (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Other assets Increase (Decrease) in Other Operating Assets Expected amortization, year two Finite-Lived Intangible Asset, Expected Amortization, Year Two In-process Research and Development Expense In Process Research and Development, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Warrants, Vested and expected to vest, Aggregate Intrinsic Value Aggregate Intrinsic Value, Warrants vested and expected to vest Aggregate Intrinsic Value, Warrants vested and expected to vest Warrants, Forfeited (in dollars per share) Weighted Average Exercise Price, Warrants Canceled Weighted Average Exercise Price, Warrants Canceled Non-controlling interests Equity, Attributable to Noncontrolling Interest Warrants, Granted (in dollars per share) Weighted Average Exercise Price, Warrants Granted Weighted Average Exercise Price, Warrants Granted Sanford Burnham Prebys Sanford Burnham Prebys [Member] Sanford Burnham Prebys Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Treasury Stock Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Clinical and R&D related liabilities Clinical and R&D Related Liabilities Clinical and R&D Related Liabilities Loss on disposal of fixed assets Gain (Loss) on Disposition of Property Plant Equipment Total share-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Benefit from income taxes Income Tax Expense (Benefit) Warrants, Vested, Aggregate Intrinsic Value Aggregate Intrinsic Value, Warrants vested Aggregate Intrinsic Value, Warrants vested Income Tax Authority [Domain] Income Tax Authority [Domain] Salaries, employee benefits and related taxes Employee-related Liabilities, Current Fair Value Measurements Fair Value Disclosures [Text Block] Name Trading Arrangement, Individual Name Equity [Abstract] Equity [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Weighted average remaining lease term for operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term Revenue excluding taxes Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Money market funds Money Market Funds [Member] Tax credit carryforward Tax Credit Carryforward, Amount Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Weighted average discount rate for operating leases (percent) Operating Lease, Weighted Average Discount Rate, Percent Intangible Assets Intangible Assets, Finite-Lived, Policy [Policy Text Block] Useful life Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Leasehold improvements Leasehold Improvements [Member] Diluted shares (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Operating Expenses: Operating Expenses [Abstract] Company Selected Measure Amount Company Selected Measure Amount Additional Paid-in Capital Additional Paid-in Capital [Member] Options, Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Proceeds from sale of NOLs Proceeds From Sale of NOLS Proceeds From Sale of NOLS Australia Research and Development Tax Incentive Research and Development Tax Incentive [Text Block] Research and Development Tax Incentive Loss from equity method investment Income (Loss) from Equity Method Investments Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Cover [Abstract] Subsequent Events Subsequent Events [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Recurring Fair Value, Recurring [Member] Other long-term liabilities Other Liabilities, Noncurrent Vested, Weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Total lease payments Lessee, Operating Lease, Liability, to be Paid Operating Lease Liabilities: Operating Lease, Liability [Abstract] Total operating expenses Operating Expenses Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Marketable securities Marketable Securities Adjustment to Compensation: Adjustment to Compensation [Axis] State State and Local Jurisdiction [Member] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Basic shares (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Operating loss Operating Income (Loss) Qilu Qilu [Member] Qilu Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block] Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Options, Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Stock Options, Weighted Average Contractual Term and Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract] Non- Controlling Interest in Subsidiary Noncontrolling Interest [Member] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] EX-101.PRE 10 lsta-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 lsta-20240331_g1.jpg begin 644 lsta-20240331_g1.jpg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᱌ <5H/P;\)>'=]: M5% '%^&/@]X4\':LFHZ5I]Q%/$DD=M'/J%S<06:.076VADD:.W4X Q$JC Z M<5T7ASP[I_A/0K'1M*M_LNG640A@AWL^U1T!9B6)]R236E10!QVK?"/POK>H M:_>7EG=.^O6QM-3@34KF.WND*+'EH%D$>_8JKY@7?@8W8K;NO"NE7GB'3=:UM9B[8BCE*&0!<[3GRDY(R,<$9.=:B@#CM'^$?A30[B&6TTQ_+M MUD6WM)[R>:UME=2K"&W=S%$"K,N$5?E)'0XJOH?P3\&>'FN_LVCF=+FS?3FB MU"[GO8X[5\;[>))G=8HFP,QQA5.T<<"NYHH YKPU\.M"\)WGVNP@NGNA#]F2 M:^U"XO'BBR#Y<9FD?8I*J2JX!VCT%4?%?P?\)^-M4?4-8TV2>>6)8+E8;VX@ MAO(U)*QW,4;JEP@R<+*K#DC'-=G10!RLWPO\-W&M:SJDEC*\VLVQM=1MFO)S M:749C6/]Y;;_ "6;8JIOV;MHQG%5O"OP?\*^#=4M]2TVQNFU&WMWLXKN_P!2 MNKV5(&*$Q!IY'.P;%VKT7+;<;FSV=% '":+\#_!F@:AIEY9Z7,)=+N&NM.CG MU"YFAL79'1A;Q/(4A0K(PV(H7IQ\JXT;CX7^&;C1AI;:$[W2X[&2QNE\NZ-ZE[%J5U' M?"D^$Y+J73XKAKFZVB>ZO;R:[GD"YV*99G=RJ[FP MN<#<<#DU#)\/] FN+^=[#=+?ZC;ZKG1^(KC71;_P#$UGM8[*2'$GS!@=RD @C QUU% '&2?!_PI<:7? M6-Q87%XEX\4DUS=ZAZ(DQ,MP\AE0H22I5QM))&,FJ[?!'P>VA+I0L;R. M);[^T_MD>JW:7S76PQ^RUG;;?9U69BLFW8JQLO[MUW1@E=WS5E>!_V>[2&^\13Z MUX>T+PQI.IQV:Q>'/"-U,EO;SV[R.+Q9DCMV2OUOHED^^@NQ.)RAPN4+E?E7CY5QW%% '-Z-\.?# MGA^_TN\T[2X[2XTNP?3+-HW?$5N[H[H%S@EFC0EB"Q(Y/)K1U;PYIVN7FDW5 M];^?/I5R;RS8NP$4QC>+=@$!ODE<8;(^;/4 UIT4 <]-\/\ 09_#IT*2PW:4 MUW]N:W\Z3F;[1]IW%MVX_O?FQG!Z8QQ4&J_#/PWK5EK]K=Z>SQ:[!5R^^$/A6_L](MC8W%I_9+2-9SZ?J% MS:7$?F',H,T,BR,'.&<,Q#D MDC-=E10!C>%/!^C>!]'_LK0K"/3M/\ .FN/ ML\9)7S)9&DD/)/5F8XZ#.!@ "L30?@[X4\,_V1]AL;H)I%S)=Z='G,W]K7D6H7]N) M;B\M_G^669Y#(S?O'&\MOQ@;L*H'=T4 <5XF^#7A#Q?J'VS5-+DED:%+:>." M]N((;N)/N1W$4;JEP@R<+*K#!(QS73Z?H]OIEU>SPO(;*6:\DU"2&U\4:G%;-.\A MD=C MP(\,Y)*[=IR>,5STRVBTRXL$TY)(X)-.U*ZM)621_,E M662*57F5W^=A(6#-DG).:?\ \*2\&1^&H- M=(;2]+M]0DU2WCTN\N+)[>Y< MN7DBDAD5X\^8XPK ;6*XQQ7?Z]\!_!'BB;5'U329KR'5$*WMD^HW0M+ MAB@0RO;B41&7:%_>[?,!4$-D UU.J>$]*UK2[/3KRT$UE9SV]S!"'90DD#K) M">",[613@\''.:UZ* .;UCX=>'/$%]JUYJ.EQWD^K:>FEWAE=R);9&=ECVYP MN&D3][

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end GRAPHIC 12 lsta-20240331_g2.jpg begin 644 lsta-20240331_g2.jpg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end XML 14 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - shares
 3 Months Ended
Mar. 31, 2024
May 09, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-33650  
Entity Registrant Name LISATA THERAPEUTICS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 22-2343568  
Entity Address, Address Line One 110 Allen Road, 2nd Floor  
Entity Address, City or Town Basking Ridge  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07920  
City Area Code 908  
Local Phone Number 842-0100  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol LSTA  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   8,307,433
Entity Central Index Key 0000320017  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Amendment Flag false  

XML 15 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
ASSETS    
Cash and cash equivalents $ 21,805 $ 22,593
Marketable securities 21,544 27,942
Prepaid and other current assets 4,210 3,389
Total current assets 47,559 53,924
Property and equipment, net 146 175
Acquired license - intangible, net 245 263
Other assets 290 332
Total assets 48,240 54,694
Liabilities    
Accounts payable 1,263 2,421
Accrued liabilities 4,070 4,169
Total current liabilities 5,333 6,590
Other long-term liabilities 164 210
Total liabilities 5,497 6,800
Commitments and Contingencies (Note 13)
Stockholders' Equity    
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,308,171 and 8,150,635 shares at March 31, 2024 and December 31, 2023, respectively; and outstanding, 8,307,433 and 8,149,897 shares at March 31, 2024 and December 31, 2023, respectively 8 8
Additional paid-in capital 577,283 576,971
Treasury stock, at cost; 738 shares at March 31, 2024 and December 31, 2023 (708) (708)
Accumulated deficit (533,482) (528,081)
Accumulated other comprehensive loss (104) (42)
Total Lisata Therapeutics, Inc. stockholders' equity 42,997 48,148
Non-controlling interests (254) (254)
Total equity 42,743 47,894
Total liabilities, non-controlling interests and stockholders' equity $ 48,240 $ 54,694
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Common stock, par value (in usd per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 8,308,171 8,150,635
Common stock outstanding (in shares) 8,307,433 8,149,897
Treasury stock (in shares) 738 738
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating Expenses:    
Research and development $ 3,241 $ 3,179
General and administrative 3,360 3,665
Total operating expenses 6,601 6,844
Operating loss (6,601) (6,844)
Other income (expense):    
Investment income, net 589 670
Other expense, net (187) (13)
Total other income 402 657
Net loss before benefit from income taxes and noncontrolling interests (6,199) (6,187)
Benefit from income taxes (798) 0
Net loss (5,401) (6,187)
Less - net income (loss) attributable to noncontrolling interests 0 0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders $ (5,401) $ (6,187)
Basic and diluted loss per share    
Lisata Therapeutics, Inc. common stockholders- basic (in usd per share) $ (0.65) $ (0.77)
Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share) $ (0.65) $ (0.77)
Weighted average common shares outstanding    
Basic shares (in shares) 8,294 7,987
Diluted shares (in shares) 8,294 7,987
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Net loss $ (5,401) $ (6,187)
Other comprehensive loss:    
Available for sale securities - net unrealized loss (13) (11)
Cumulative translation adjustment arising during the period (49) (12)
Total other comprehensive loss (62) (23)
Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders $ (5,463) $ (6,210)
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Total Lisata Therapeutics, Inc. Stockholders' Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Common stock, beginning balance (in shares) at Dec. 31, 2022     7,867,000          
Beginning balance at Dec. 31, 2022 $ 66,324 $ 66,578 $ 8 $ 574,548 $ (29) $ (507,241) $ (708) $ (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (6,187) (6,187)       (6,187)    
Share-based compensation (in shares)     132,000          
Share-based compensation 589 589   589        
Unrealized loss on marketable securities (11) (11)     (11)      
Foreign currency translation adjustment (12) (12)     (12)      
Common stock, ending balance (in shares) at Mar. 31, 2023     7,999,000          
Ending balance at Mar. 31, 2023 $ 60,703 60,957 $ 8 575,137 (52) (513,428) (708) (254)
Common stock, beginning balance (in shares) at Dec. 31, 2023 8,149,897   8,151,000          
Beginning balance at Dec. 31, 2023 $ 47,894 48,148 $ 8 576,971 (42) (528,081) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (5,401) (5,401)       (5,401)    
Share-based compensation (in shares)     157,000          
Share-based compensation 312 312   312        
Unrealized loss on marketable securities (13) (13)     (13)      
Foreign currency translation adjustment $ (49) (49)     (49)      
Common stock, ending balance (in shares) at Mar. 31, 2024 8,307,433   8,308,000          
Ending balance at Mar. 31, 2024 $ 42,743 $ 42,997 $ 8 $ 577,283 $ (104) $ (533,482) $ (708) $ (254)
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net loss $ (5,401) $ (6,187)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation 454 675
Depreciation and amortization 46 48
Loss on disposal of fixed assets 0 3
Loss from equity method investment 100 0
Amortization/accretion on marketable securities (152) (167)
Changes in operating assets and liabilities:    
Prepaid and other current assets (872) (1,652)
Other assets 41 167
Accounts payable, accrued liabilities and other liabilities (1,243) (1,083)
Net cash used in operating activities (7,027) (8,196)
Cash flows from investing activities:    
Purchase of marketable securities (18,824) (30,121)
Sale of marketable securities 25,360 34,410
Investment in Impilo Therapeutics (100) 0
Net cash provided by investing activities 6,436 4,289
Cash flows from financing activities:    
Tax withholding payments on net share settlement equity awards (142) (85)
Net cash used in financing activities (142) (85)
Effect of exchange rate changes on cash (55) (7)
Net decrease in cash and cash equivalents (788) (3,999)
Cash and cash equivalents at beginning of period 22,593 32,154
Cash and cash equivalents at end of period $ 21,805 $ 28,155
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
The Business
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
The Business The Business
Overview
Lisata Therapeutics, Inc. (together with its subsidiaries, the “Company”) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's lead investigational product candidate, certepetide (LSTA1), is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are expected to be unaffected. Certepetide also has been shown to modify the tumor microenvironment (“TME”), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). The Company and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics. To date, certepetide has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring certepetide as a means to enable a variety of treatment modalities to treat a range of solid tumors more effectively. Currently, certepetide, is the subject of several Phase 2 clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens.
The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. The Company's goal is to develop and commercialize products that address important unmet medical needs.
Basis of Presentation
The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of March 31, 2024, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2023 and 2022 included in our 2023 Form 10-K. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.
Principles of Consolidation
The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.
Foreign Currency Remeasurement
The Company’s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Cash and Cash Equivalents
Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.
Concentration of Risks
The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.
Marketable Securities
The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.
Property and Equipment
The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:
Furniture and fixtures10 years
Computer equipment3 years
Software3 years
Leasehold improvementsLife of lease
Long-lived Assets
Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.
Share-Based Compensation  
The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.
Loss Per Share
Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.
Treasury Stock
Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.
Research and Development Costs 
Research and development (“R&D”) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.
To further drive the Company’s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.
In-process Research and Development Expense
Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a “business” as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.
Intangible Asset
The Company’s intangible asset consists of a single asset, a license agreement with Qilu Pharmaceutical, Co., Ltd. (“Qilu”) acquired in the Company's acquisition of Cend Therapeutics, Inc (the “Cend Merger”), with a value of $0.4 million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $17 thousand for the three months ended March 31, 2024 and $18 thousand for the three months ended March 31, 2023. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable. The projected amortization expense is $71 thousand per year for the next 3.5 years.
Revenue Recognition
The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.
If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three months ended March 31, 2024 and 2023.
Milestones
At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company’s collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company’s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March 31, 2024 and March 31, 2023, the Company has not recognized revenue related to milestones.
Royalties
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Available-for-Sale-Securities
 3 Months Ended
Mar. 31, 2024
Debt Securities, Available-for-Sale [Abstract]  
Available-for-Sale-Securities Available-for-Sale-Securities
The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):
March 31, 2024December 31, 2023
CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueCostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Corporate debt securities$33,750 $— $(18)$33,732 $37,791 $3 $(8)$37,786 
Commercial paper— — — — 1,981 — — 1,981 
Money market funds5,242 — — 5,242 4,268 — — 4,268 
Municipal debt securities247 — — 247 622 — — 622 
Total$39,239 $— $(18)$39,221 $44,662 $3 $(8)$44,657 


Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in the Company's Consolidated Balance Sheets (in thousands):
March 31, 2024December 31, 2023
Cash equivalents$17,677 $16,715 
Marketable securities21,544 27,942 
Total$39,221 $44,657 



The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):
March 31, 2024
Amortized CostEstimated Fair Value
Less than one year$39,239 $39,221 
Greater than one year— — 
Total$39,239 $39,221 
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment
 3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
Property and Equipment Property and Equipment
Property and equipment consisted of the following (in thousands):
March 31, 2024December 31, 2023
Computer equipment589 589 
Leasehold improvements72 72 
Property and equipment, gross661 661 
Accumulated depreciation(515)(486)
Property and equipment, net$146 $175 

The Company’s results included depreciation expense of approximately $29 thousand and $30 thousand for the three months ended March 31, 2024 and 2023, respectively.
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income (Loss) Per Share
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Income (Loss) Per Share Income (Loss) Per Share
For the three months ended March 31, 2024 and 2023, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive in the periods presented. At March 31, 2024 and 2023, the Company excluded the following potentially dilutive securities (in thousands):
 March 31
 20242023
Stock options1,454 1,493 
Warrants1,422 1,424 
Restricted stock units354 237 
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:
Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.
Level 3 inputs are defined as unobservable inputs for the assets or liabilities.
Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.
The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 were as follows (in thousands):
March 31, 2024December 31, 2023
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Cash equivalents$17,677 $— $— $17,677 $16,715 $— $— $16,715 
Marketable securities - available for sale— 21,544 — 21,544 — 27,942 — 27,942 
$17,677 $21,544 $— $39,221 $16,715 $27,942 $— $44,657 

The carrying values of accounts payable and accrued expenses approximate fair value as of March 31, 2024 and December 31, 2023, due to the short maturity nature of these items.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accrued Liabilities
 3 Months Ended
Mar. 31, 2024
Accrued Liabilities [Abstract]  
Accrued Liabilities Accrued Liabilities
Accrued liabilities as of March 31, 2024 and December 31, 2023 were as follows (in thousands):
March 31, 2024December 31, 2023
Salaries, employee benefits and related taxes$1,324 $2,665 
Clinical and R&D related liabilities1,724 1,046 
Accounting & tax consulting liabilities92 57 
Legal settlement500 — 
Operating lease liabilities — current172 168 
Other258 233 
Total$4,070 $4,169 
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Operating Leases
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Operating Leases Operating Leases
The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.
Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):
March 31, 2024December 31, 2023
Right-of-Use Assets:
Other assets$267 $308 
Total Right-of-Use Asset$267 $308 
Operating Lease Liabilities:
Accrued liabilities$172 $168 
Other long-term liabilities92 137 
Total Operating Lease Liabilities$264 $305 
    
As of March 31, 2024, the weighted average remaining lease term for our operating lease was 1.5 years, and the weighted average discount rate for our operating lease was 9.625%. As of December 31, 2023, the weighted average remaining lease term for our operating leases was 1.75 years, and the weighted average discount rate for our operating leases was 9.625%.
Future minimum lease payments under the lease agreement as of March 31, 2024 were as follows (in thousands):
Years endedOperating Leases
2024143 
2025143 
Total lease payments286 
Less: Amounts representing interest(22)
Present value of lease liabilities$264 
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders' Equity
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Stockholders' Equity Stockholders' Equity
Equity Issuances
At The Market Offering Agreement
On June 4, 2021, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC, as sales agent, in connection with an “at the market offering” under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0 million. As of the date of this filing and so long as the Company’s public float remains below $75.0 million, the Company is subject to limitations pursuant to General Instruction I.B.6 of Form S-3 (the “Baby Shelf Limitation”), which limits the amount the Company can offer to up to one-third of its public float during any trailing 12-month period. Subsequent to the filing of the Company's Registration Statement on Form S-3 (File No. 333-279034) on May 1, 2024, the aggregate market value of its outstanding common stock held by non-affiliates was approximately $26.7 million. Pursuant to the Baby Shelf Limitation, since the aggregate market value of the Company's outstanding common stock held by non-affiliates was below $75.0 million at the time of such S-3 filing, the aggregate amount of securities that the Company is permitted to offer and sell is now $8,915,094, which is equal to one-third of the aggregate market value of our common stock held by non-affiliates as of March 21, 2024. If the Company’s public float exceeds $75.0 million on a future measurement date, it will no longer be subject to the Baby Shelf Limitation. There were no issuances of common stock under the ATM Agreement for the three months ended March 31, 2024. Since inception, the Company has issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774.
Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2024:
Stock OptionsWarrants
SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (In Thousands)SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 20231,322,501 $10.81 6.06$164.1 1,421,744 $42.51 2.42$— 
Changes during the period:
Granted132,575 3.07 — — 
Exercised— — — — 
Forfeited— — — — 
Expired(1,163)1,165.50 — — 
Outstanding at March 31, 20241,453,913 $9.18 6.18$232.1 1,421,744 $42.51 2.00$— 
Vested at March 31, 2024
or expected to vest in the future		1,443,689 $9.22 6.16$231.5 1,421,744 $42.51 2.00$— 
Vested at March 31, 20241,285,911 $9.92 5.75$215.9 1,421,744 $42.51 2.00$— 


Restricted Stock
During the three months ended March 31, 2024 and 2023, the Company issued restricted stock for services as follows (in thousands, except share data):
Three Months Ended March 31,
  20242023
Number of restricted stock issued203,800 159,950 
Value of restricted stock issued$628 $480 

The vesting terms of restricted stock issuances are generally between one and four years.

The following is a summary of the changes in non-vested restricted stock for the three months ended March 31, 2024:
Restricted Stock SharesWeighted Average Grant-Date Fair Value
Non-vested at December 31, 2023125,775 $5.86 
Changes during the Year:
Granted203,800 $3.08 
Vested(99,686)$5.22 
Forfeited— $— 
Non-vested at March 31, 2024229,889 $3.67 
Restricted Stock Units
During the three months ended March 31, 2024 and 2023, the Company issued restricted stock units for services as follows (in thousands, except share data):
Three Months Ended March 31,
20242023
Number of restricted stock units issued205,300 188,850 
Value of restricted stock units issued $632 $567 

The weighted average estimated fair value of restricted stock units issued for services in the three months ended March 31, 2024 and 2023 was $3.08 and $3.00 per share, respectively. The fair value of the restricted stock units was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.

The following is a summary of the changes in non-vested restricted stock units for the three months ended March 31, 2024:
Restricted Stock UnitsWeighted Average Grant-Date Fair Value
Non-vested at December 31, 2023112,800 $3.37 
Changes during the Year:
Granted97,400 $3.08 
Vested(100,000)$3.00 
Forfeited— $— 
Non-vested at March 31, 2024110,200 $3.45 
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
Share-Based Compensation
The Company utilizes share-based compensation in the form of stock options, restricted stock, and restricted stock units. The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
Research and development$86 $187 
General and administrative368 488 
Total share-based compensation expense$454 $675 

Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March 31, 2024 were as follows (in thousands):
Stock OptionsRestricted Stock UnitsRestricted Stock
Unrecognized compensation cost$371 $290 $751 
Expected weighted-average period in years of compensation cost to be recognized2.280.922.17
Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March 31, 2024 and 2023 were as follows (in thousands):
Stock Options
Three Months Ended March 31,
20242023
Total fair value of shares vested$199 $324 
Weighted average estimated fair value of shares granted$2.16 $0.78 

Valuation Assumptions
The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.
As of December 31, 2023 and 2022, the Company had approximately $43.7 million and $33.7 million respectively, of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $88.2 million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in approximately $34.0 million of remaining Federal NOLs as of December 31, 2022. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations.
As of December 31, 2022, Cend Therapeutics, Inc. (“Cend”) had approximately $3.6 million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $3.1 million of Federal and $4.3 million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years. Using a fair market value of $36.1 million and applying an applicable federal rate of 2.54% Cend will have an annual limitation of approximately $917 thousand each year. The Federal NOL of $459 thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation and does not expire. As of December 31, 2023 and 2022, Cend’s wholly owned Australian subsidiary had approximately $2.4 million and $1.8 million, respectively, of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.
As of December 31, 2023, the Company had federal research and development credit carryforwards of $0.5 million expiring from 2027 through 2034 if unutilized, and state research and development credit carryforwards of $0.1 million, which carryforward indefinitely. Utilization of these credits may be subject to an annual limitation based on changes in ownership.
As of December 31, 2023 and 2022, the Company had State NOLs available in New Jersey of $19.4 million and $35.5 million, respectively, California of $9.2 million and $9.2 million, respectively, and New York City of $1.9 million and $1.9 million, respectively, to offset future taxable income expiring from 2032 through 2043. The usage of the Company’s NOLs is limited given the change in ownership.
The Company applies the FASB’s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.
As of December 31, 2023 and 2022, the Company’s uncertain tax positions were $344 thousand and $344 thousand, respectively. The uncertain tax positions are due to the acquisition of Cend related to Federal and state credits and certain state
NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.
For years prior to 2020, the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of three to four years from the date of the tax return filing.
On March 4, 2024, the Company received final approval from the New Jersey Economic Development Authority (“NJEDA”) under the Technology Business Tax Certificate Transfer Program (“Program”) to sell $8.9 million of its New Jersey net operating losses (“NJ NOLs”), which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $0.7 million. The sale of NJ NOLs resulted in a $0.8 million deferred income tax benefit and a loss on sale of $0.1 million recorded in other income (expense) in the consolidated financial statements.
On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for tax years beginning on or after January 1, 2023. For tax years beginning after December 31, 2021, the Tax Cuts & Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or 15 years beginning in 2022. Since the Company is in a net operating loss position, the capitalization of research and development costs did not have a material impact on the Company’s results of operations for the year ended December 31, 2023. The Company will continue to monitor the possible future impact of changes in tax legislation.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Australia Research and Development Tax Incentive
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Australia Research and Development Tax Incentive Australia Research and Development Tax IncentiveThe Company’s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between 43.5% to 48.5% (depending upon the income tax rate) for qualified research and development activities. As of the three months ended March 31, 2024 and 2023, the Company had $1.0 million and $1.0 million, respectively, recorded as an income tax incentive receivable in prepaid and other current assets in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed.
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Contingencies
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Contingencies
Contingencies
From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. The Company has elected to recognize expense for legal fees as incurred when the legal services are provided.
In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (“Lingmed”) claiming Lingmed was entitled to a success fee based on Cend’s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend’s response to the complaint was filed on June 6, 2022 and denied all of Lingmed’s material allegations. Lingmed filed an answer to Cend’s response on July 11, 2022, denying all of the Company’s material allegations. On March 25, 2024 the Company entered into a settlement agreement whereby the Company is required to pay Lingmed $0.5 million within 30 days of the effective date and the Company effected payment on April 4, 2024. Lingmed is also entitled to 5.0% of any future milestone payments received by the Company under the license agreement with Qilu in addition to a sum of $250 thousand with respect to the first future milestone received by the Company. On April 9, 2024, pursuant to the parties’ joint request, the Court entered a dismissal with prejudice of the entire action as to all parties and all claims and the matter was settled.
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Technology Transfer Agreement
 3 Months Ended
Mar. 31, 2024
Technology Transfer Agreement [Abstract]  
Technology Transfer Agreement Technology Transfer Agreement
Impilo Therapeutics
In July 2023, the Company entered into a technology transfer agreement with Impilo Therapeutics (“Impilo”) under which the Company transferred its rights to its tumor penetrating nanocomplex (TPN) platform to Impilo. As consideration for the technology transfer, Impilo issued a total of 766,000 shares of its pre-seed preferred stock to the Company. On October 3, 2023
in connection with the Sanford Burnham Prebys license agreement (Note 15) Impilo cancelled the original stock certificate for 766,000 shares and reissued 574,500 shares of its pre-seed preferred stock to the Company.
On March 15, 2024, the Company purchased a Simple Agreement for Future Equity ("SAFE") from Impilo for $100,000. As of March 31, 2024 and December 31, 2023 the Company owned 38.6% of Impilo. This investment was expensed under the equity method of accounting for the three months ended March 31, 2024 in other expense,net in the accompanying statement of operations. The SAFE has a valuation cap of $30.0 million and an 80% discount rate.
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
License Agreements
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
License Agreements License Agreements
Sanford Burnham Prebys
In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (“SBP”) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of certepetide. At the time the license agreement was entered into, Cend’s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6 million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company’s pre-seed preferred stock in Impilo on October 3, 2023.
The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days’ prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.
SBP did not own shares of the Company’s common stock as of March 31, 2024.
Research Collaboration and License Agreement
Exclusive License and Collaboration Agreement
In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the “Qilu Agreement”) in which Cend granted an exclusive license to Qilu for the development and commercialization of certepetide in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of certepetide in its Territory. In consideration for the license, Qilu made an upfront payment of $10.0 million to Cend, which was recognized as revenue by Cend prior to the Company's acquisition of Cend on September 15, 2022 (the “Cend Merger”). In addition, Cend received and recognized as revenue a $5.0 million development milestone prior to the Cend Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $96.0 million and $125.0 million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.
On March 25, 2024 the Company entered into a settlement agreement with Lingmed whereby Lingmed is entitled to 5.0% of any future milestone payments received by the Company under the Qilu Agreement, in addition, Lingmed is also entitled to a sum of $250 thousand with respect to the first future milestone received by the Company.
Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined
period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate simultaneously.
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Research Collaboration and License Agreement
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Research Collaboration and License Agreement License Agreements
Sanford Burnham Prebys
In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (“SBP”) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of certepetide. At the time the license agreement was entered into, Cend’s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6 million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company’s pre-seed preferred stock in Impilo on October 3, 2023.
The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days’ prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.
SBP did not own shares of the Company’s common stock as of March 31, 2024.
Research Collaboration and License Agreement
Exclusive License and Collaboration Agreement
In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the “Qilu Agreement”) in which Cend granted an exclusive license to Qilu for the development and commercialization of certepetide in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of certepetide in its Territory. In consideration for the license, Qilu made an upfront payment of $10.0 million to Cend, which was recognized as revenue by Cend prior to the Company's acquisition of Cend on September 15, 2022 (the “Cend Merger”). In addition, Cend received and recognized as revenue a $5.0 million development milestone prior to the Cend Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $96.0 million and $125.0 million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.
On March 25, 2024 the Company entered into a settlement agreement with Lingmed whereby Lingmed is entitled to 5.0% of any future milestone payments received by the Company under the Qilu Agreement, in addition, Lingmed is also entitled to a sum of $250 thousand with respect to the first future milestone received by the Company.
Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined
period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate simultaneously.
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Subsequent Events
 3 Months Ended
Mar. 31, 2024
Subsequent Events [Abstract]  
Subsequent Events Subsequent EventsOn April 15, 2024, the Company’s Board of Directors appointed James Nisco as the Company’s Senior Vice President, Finance and Treasury and Chief Accounting Officer, effective immediately. Effective as of April 15, 2024, Mr. Nisco shall serve as the Company’s principal financial officer and principal accounting officer.
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net Income (Loss) Attributable to Parent $ (5,401) $ (6,187)
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of March 31, 2024, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2023 and 2022 included in our 2023 Form 10-K. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.
Principles of Consolidation
Principles of Consolidation
The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation
Foreign Currency Remeasurement
Foreign Currency Remeasurement
The Company’s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.
Cash and Cash Equivalents
Cash and Cash Equivalents
Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.
Concentration of Risks
Concentration of Risks
The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.
Marketable Securities
Marketable Securities
The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.
Property and Equipment
Property and Equipment
The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred.
Long-lived Assets
Long-lived Assets
Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.
Share-Based Compensation
Share-Based Compensation  
The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.
Loss Per Share
Loss Per Share
Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.
Treasury Stock
Treasury Stock
Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.
Research and Development Costs
Research and Development Costs 
Research and development (“R&D”) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.
To further drive the Company’s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.
In-process Research and Development Expense
In-process Research and Development Expense
Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a “business” as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.
Intangible Assets The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.
Revenue Recognition
Revenue Recognition
The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.
If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.
Milestones, Royalties
Milestones
At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company’s collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company’s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March 31, 2024 and March 31, 2023, the Company has not recognized revenue related to milestones.
Royalties
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.
Leases
The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Property, Plant and Equipment The estimated useful lives of property and equipment are as follows:
Furniture and fixtures10 years
Computer equipment3 years
Software3 years
Leasehold improvementsLife of lease
Property and equipment consisted of the following (in thousands):
March 31, 2024December 31, 2023
Computer equipment589 589 
Leasehold improvements72 72 
Property and equipment, gross661 661 
Accumulated depreciation(515)(486)
Property and equipment, net$146 $175 
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Available-for-Sale-Securities (Tables)
 3 Months Ended
Mar. 31, 2024
Debt Securities, Available-for-Sale [Abstract]  
Schedule of Available-for-sale Securities Reconciliation
The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):
March 31, 2024December 31, 2023
CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueCostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Corporate debt securities$33,750 $— $(18)$33,732 $37,791 $3 $(8)$37,786 
Commercial paper— — — — 1,981 — — 1,981 
Money market funds5,242 — — 5,242 4,268 — — 4,268 
Municipal debt securities247 — — 247 622 — — 622 
Total$39,239 $— $(18)$39,221 $44,662 $3 $(8)$44,657 
Schedule of Marketable Securities
Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in the Company's Consolidated Balance Sheets (in thousands):
March 31, 2024December 31, 2023
Cash equivalents$17,677 $16,715 
Marketable securities21,544 27,942 
Total$39,221 $44,657 
Investments Classified by Contractual Maturity Date
The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):
March 31, 2024
Amortized CostEstimated Fair Value
Less than one year$39,239 $39,221 
Greater than one year— — 
Total$39,239 $39,221 
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment (Tables)
 3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment The estimated useful lives of property and equipment are as follows:
Furniture and fixtures10 years
Computer equipment3 years
Software3 years
Leasehold improvementsLife of lease
Property and equipment consisted of the following (in thousands):
March 31, 2024December 31, 2023
Computer equipment589 589 
Leasehold improvements72 72 
Property and equipment, gross661 661 
Accumulated depreciation(515)(486)
Property and equipment, net$146 $175 
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income (Loss) Per Share (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share At March 31, 2024 and 2023, the Company excluded the following potentially dilutive securities (in thousands):
 March 31
 20242023
Stock options1,454 1,493 
Warrants1,422 1,424 
Restricted stock units354 237 
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Assets Measured at Fair Value on Recurring Basis
The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 were as follows (in thousands):
March 31, 2024December 31, 2023
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Cash equivalents$17,677 $— $— $17,677 $16,715 $— $— $16,715 
Marketable securities - available for sale— 21,544 — 21,544 — 27,942 — 27,942 
$17,677 $21,544 $— $39,221 $16,715 $27,942 $— $44,657 
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accrued Liabilities (Tables)
 3 Months Ended
Mar. 31, 2024
Accrued Liabilities [Abstract]  
Schedule of Accrued Liabilities
Accrued liabilities as of March 31, 2024 and December 31, 2023 were as follows (in thousands):
March 31, 2024December 31, 2023
Salaries, employee benefits and related taxes$1,324 $2,665 
Clinical and R&D related liabilities1,724 1,046 
Accounting & tax consulting liabilities92 57 
Legal settlement500 — 
Operating lease liabilities — current172 168 
Other258 233 
Total$4,070 $4,169 
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Operating Leases (Tables)
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet
Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):
March 31, 2024December 31, 2023
Right-of-Use Assets:
Other assets$267 $308 
Total Right-of-Use Asset$267 $308 
Operating Lease Liabilities:
Accrued liabilities$172 $168 
Other long-term liabilities92 137 
Total Operating Lease Liabilities$264 $305 
Schedule of Future Minimum Lease Payments Under Lease Agreements
Future minimum lease payments under the lease agreement as of March 31, 2024 were as follows (in thousands):
Years endedOperating Leases
2024143 
2025143 
Total lease payments286 
Less: Amounts representing interest(22)
Present value of lease liabilities$264 
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders' Equity (Tables)
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Schedule of Stock Option and Warrants Activity The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2024:
Stock OptionsWarrants
SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (In Thousands)SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 20231,322,501 $10.81 6.06$164.1 1,421,744 $42.51 2.42$— 
Changes during the period:
Granted132,575 3.07 — — 
Exercised— — — — 
Forfeited— — — — 
Expired(1,163)1,165.50 — — 
Outstanding at March 31, 20241,453,913 $9.18 6.18$232.1 1,421,744 $42.51 2.00$— 
Vested at March 31, 2024
or expected to vest in the future		1,443,689 $9.22 6.16$231.5 1,421,744 $42.51 2.00$— 
Vested at March 31, 20241,285,911 $9.92 5.75$215.9 1,421,744 $42.51 2.00$— 
Schedule of Restricted Stock Activity
During the three months ended March 31, 2024 and 2023, the Company issued restricted stock for services as follows (in thousands, except share data):
Three Months Ended March 31,
  20242023
Number of restricted stock issued203,800 159,950 
Value of restricted stock issued$628 $480 
The following is a summary of the changes in non-vested restricted stock for the three months ended March 31, 2024:
Restricted Stock SharesWeighted Average Grant-Date Fair Value
Non-vested at December 31, 2023125,775 $5.86 
Changes during the Year:
Granted203,800 $3.08 
Vested(99,686)$5.22 
Forfeited— $— 
Non-vested at March 31, 2024229,889 $3.67 
Schedule of Restricted Stock Units Activity
During the three months ended March 31, 2024 and 2023, the Company issued restricted stock units for services as follows (in thousands, except share data):
Three Months Ended March 31,
20242023
Number of restricted stock units issued205,300 188,850 
Value of restricted stock units issued $632 $567 
The following is a summary of the changes in non-vested restricted stock units for the three months ended March 31, 2024:
Restricted Stock UnitsWeighted Average Grant-Date Fair Value
Non-vested at December 31, 2023112,800 $3.37 
Changes during the Year:
Granted97,400 $3.08 
Vested(100,000)$3.00 
Forfeited— $— 
Non-vested at March 31, 2024110,200 $3.45 
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule Share-based Compensation Expense The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
Research and development$86 $187 
General and administrative368 488 
Total share-based compensation expense$454 $675 
Schedule of Total Compensation Cost Related to Nonvested Awards
Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March 31, 2024 were as follows (in thousands):
Stock OptionsRestricted Stock UnitsRestricted Stock
Unrecognized compensation cost$371 $290 $751 
Expected weighted-average period in years of compensation cost to be recognized2.280.922.17
Schedule of Fair Value of Share-based Compensation Awards
Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March 31, 2024 and 2023 were as follows (in thousands):
Stock Options
Three Months Ended March 31,
20242023
Total fair value of shares vested$199 $324 
Weighted average estimated fair value of shares granted$2.16 $0.78 
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Property and Equipment (Details)
Mar. 31, 2024
Furniture and fixtures  
Property, Plant and Equipment [Line Items]  
Useful life 10 years
Computer equipment  
Property, Plant and Equipment [Line Items]  
Useful life 3 years
Software  
Property, Plant and Equipment [Line Items]  
Useful life 3 years
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Accounting Policies [Abstract]    
Intangible assets, net $ 400,000  
Intangible asset, useful life 5 years  
Amortization of intangible assets $ 17,000 $ 18,000
Expected amortization, remainder of fiscal year 71,000  
Expected amortization, year one 71,000  
Expected amortization, year two 71,000  
Expected amortization, year three 71,000  
Revenue excluding taxes 0 0
Revenue from collaborative arrangement 0 0
Disaggregation of Revenue [Line Items]    
Revenue excluding taxes 0 $ 0
Royalty    
Accounting Policies [Abstract]    
Revenue excluding taxes 0  
Disaggregation of Revenue [Line Items]    
Revenue excluding taxes $ 0  
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]    
Cost $ 39,239 $ 44,662
Gross Unrealized Gains 0 3
Gross Unrealized Losses (18) (8)
Estimated Fair Value 39,221 44,657
Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Cost 33,750 37,791
Gross Unrealized Gains 0 3
Gross Unrealized Losses (18) (8)
Estimated Fair Value 33,732 37,786
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Cost 0 1,981
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Estimated Fair Value 0 1,981
Money market funds    
Debt Securities, Available-for-sale [Line Items]    
Cost 5,242 4,268
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Estimated Fair Value 5,242 4,268
Municipal debt securities    
Debt Securities, Available-for-sale [Line Items]    
Cost 247 622
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Estimated Fair Value $ 247 $ 622
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Debt Securities, Available-for-Sale [Abstract]    
Cash equivalents $ 17,677 $ 16,715
Marketable securities 21,544 27,942
Total $ 39,221 $ 44,657
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Amortized Cost    
Less than one year $ 39,239  
Greater than one year 0  
Cost 39,239 $ 44,662
Estimated Fair Value    
Less than one year 39,221  
Greater than one year 0  
Total $ 39,221 $ 44,657
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 661   $ 661
Accumulated depreciation (515)   (486)
Property and equipment, net 146   175
Depreciation 29 $ 30  
Computer equipment      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 589   589
Leasehold improvements      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 72   $ 72
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income (Loss) Per Share (Details) - shares
shares in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 1,454 1,493
Warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 1,422 1,424
Restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 354 237
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements (Details) - Recurring - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents $ 17,677 $ 16,715
Marketable securities - available for sale 21,544 27,942
Assets, fair value disclosure 39,221 44,657
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 17,677 16,715
Marketable securities - available for sale 0 0
Assets, fair value disclosure 17,677 16,715
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Marketable securities - available for sale 21,544 27,942
Assets, fair value disclosure 21,544 27,942
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Marketable securities - available for sale 0 0
Assets, fair value disclosure $ 0 $ 0
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accrued Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Accrued Liabilities [Abstract]    
Salaries, employee benefits and related taxes $ 1,324 $ 2,665
Clinical and R&D related liabilities 1,724 1,046
Accounting & tax consulting liabilities 92 57
Legal settlement 500 0
Operating lease liabilities — current 172 168
Other 258 233
Total $ 4,070 $ 4,169
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Operating Leases - Balance Sheet Presentation (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Right-of-Use Assets:    
Right-of-use assets $ 267 $ 308
Right-of-use assets, balance sheet line item Other assets Other assets
Operating Lease Liabilities:    
Accrued liabilities $ 172 $ 168
Operating lease liabilities, current, balance sheet line item Accrued liabilities Accrued liabilities
Other long-term liabilities $ 92 $ 137
Operating lease liabilities, noncurrent, balance sheet line item Other long-term liabilities Other long-term liabilities
Total Operating Lease Liabilities $ 264 $ 305
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Operating Leases - Narrative (Details)
Mar. 31, 2024
Dec. 31, 2023
Leases [Abstract]    
Weighted average remaining lease term for operating leases (in years) 1 year 6 months 1 year 9 months
Weighted average discount rate for operating leases (percent) 9.625% 9.625%
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Operating Leases - Future Minimum Lease Payments (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Finance Minimum Lease Payments    
2024 $ 143  
2025 143  
Total lease payments 286  
Less: Amounts representing interest (22)  
Present value of lease liabilities $ 264 $ 305
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders' Equity - Equity Issuances (Details) - USD ($)
 3 Months Ended 34 Months Ended
Mar. 31, 2024
Mar. 31, 2024
Mar. 24, 2024
May 01, 2024
Mar. 21, 2024
Jun. 04, 2021
Class of Stock [Line Items]            
Percentage held by non-affiliates         33.00%  
Subsequent event            
Class of Stock [Line Items]            
Outstanding stock threshold       $ 75,000,000    
ATM Agreement            
Class of Stock [Line Items]            
Aggregate offering amount authorized per agreement           $ 50,000,000
Sale of stock available for sale         $ 8,915,094  
Stock issued (in shares) 0 64,394        
Net proceeds from issuance of common stock     $ 270,774      
ATM Agreement | Subsequent event            
Class of Stock [Line Items]            
Common stock, value, outstanding       $ 26,700,000    
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders' Equity - Stock Options and Warrants Narrative (Details) - Restricted Stock
 3 Months Ended
Mar. 31, 2024
Minimum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Vesting term 1 year
Maximum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Vesting term 4 years
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders' Equity - Stock Options and Warrants (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Stock Options, Shares    
Options, Outstanding, Beginning of Period (in shares) 1,322,501  
Options, Granted (in shares) 132,575  
Options, Exercised (in shares) 0  
Options, Forfeited (in shares) 0  
Options, Expired (in shares) (1,163)  
Options, Outstanding, End of Period (in shares) 1,453,913 1,322,501
Options, Vested and expected to vest (in shares) 1,443,689  
Options, Vested (in shares) 1,285,911  
Stock Options, Weighted Average Exercise Price    
Options, Outstanding. Beginning of Period (in dollars per share) $ 10.81  
Options, Granted (in dollars per share) 3.07  
Options, Exercised (in dollars per share) 0  
Options, Forfeited (in dollars per share) 0  
Options, Expired (in dollars per share) 1,165.5  
Options, Outstanding, End of Period (in dollars per share) 9.18 $ 10.81
Options, Vested and expected to vest (in dollars per share) 9.22  
Options, Vested (in dollars per share) $ 9.92  
Stock Options, Weighted Average Contractual Term and Intrinsic Value    
Options, Outstanding, Weighted Average Remaining Contractual Term 6 years 2 months 4 days 6 years 21 days
Options, Vested and expected to vest, Weighted Average Remaining Contractual Term 6 years 1 month 28 days  
Options, Vested, Weighted Average Remaining Contractual Term 5 years 9 months  
Options, Outstanding, Aggregate Intrinsic Value $ 232,100 $ 164,100
Options, Vested and expected to vest, Aggregate Intrinsic Value 231,500  
Options, Vested, Aggregate Intrinsic Value $ 215,900  
Warrants, Shares    
Warrants, Outstanding, Beginning of Period (in shares) 1,421,744  
Warrants, Granted (in shares) 0  
Warrants, Exercised (in shares) 0  
Warrants, Forfeited (in shares) 0  
Warrants, Expired (in shares) 0  
Warrants, Outstanding, End of Period (in shares) 1,421,744 1,421,744
Warrants, Vested and expected to vest (in shares) 1,421,744  
Warrants, Vested (in shares) 1,421,744  
Warrants, Weighted Average Exercise Price    
Warrants Outstanding, Beginning of Period (in dollars per share) $ 42.51  
Warrants, Granted (in dollars per share) 0  
Warrants, Exercised (in dollars per share) 0  
Warrants, Forfeited (in dollars per share) 0  
Warrants, Expired (in dollars per share) 0  
Warrants Outstanding, End of Period (in dollars per share) 42.51 $ 42.51
Warrants, Weighted Average Exercise Price, Vested or expected to vest in the future (in dollars per share) 42.51  
Warrants, Vested, Weighted Average Exercise Price (in dollars per share) $ 42.51  
Warrants, Weighted Average Contractual Term and Intrinsic Value    
Warrants, Outstanding, Weighted Average Remaining Contractual Term 2 years 2 years 5 months 1 day
Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term 2 years  
Warrants, Vested, Weighted Average Remaining Contractual Term 2 years  
Warrants Outstanding, Aggregate Intrinsic Value $ 0 $ 0
Warrants, Vested and expected to vest, Aggregate Intrinsic Value 0  
Warrants, Vested, Aggregate Intrinsic Value $ 0  
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Restricted stock units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares issued (in shares) 205,300 188,850
Value of shares issued $ 632 $ 567
Weighted average estimated fair value (in dollars per share) $ 3.08  
Vesting term 1 year  
Restricted Stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares issued (in shares) 203,800 159,950
Value of shares issued $ 628 $ 480
Weighted average estimated fair value (in dollars per share) $ 3.08 $ 3.00
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders' Equity - Restricted Stock and Restricted Stock Unit Activity (Details) - $ / shares
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Restricted Stock    
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]    
Beginning balance (in shares) 125,775  
Granted (in shares) 203,800  
Vested (in shares) (99,686)  
Forfeited (in shares) 0  
Ending balance (in shares) 229,889  
Weighted-Average    
Beginning balance, Weighted average grant date fair value (in dollars per share) $ 5.86  
Granted, Weighted average grant date fair value (in dollars per share) 3.08 $ 3.00
Vested, Weighted average grant date fair value (in dollars per share) 5.22  
Forfeited, Weighted average grant date fair value (in dollars per share) 0  
Ending balance, Weighted average grant date fair value (in dollars per share) $ 3.67  
Restricted stock units    
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]    
Beginning balance (in shares) 112,800  
Granted (in shares) 97,400  
Vested (in shares) (100,000)  
Forfeited (in shares) 0  
Ending balance (in shares) 110,200  
Weighted-Average    
Beginning balance, Weighted average grant date fair value (in dollars per share) $ 3.37  
Granted, Weighted average grant date fair value (in dollars per share) 3.08  
Vested, Weighted average grant date fair value (in dollars per share) 3.00  
Forfeited, Weighted average grant date fair value (in dollars per share) 0  
Ending balance, Weighted average grant date fair value (in dollars per share) $ 3.45  
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total share-based compensation expense $ 454 $ 675
Research and development    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total share-based compensation expense 86 187
General and administrative    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total share-based compensation expense $ 368 $ 488
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
USD ($)
Stock options  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized compensation cost $ 371
Expected weighted-average period in years of compensation cost to be recognized 2 years 3 months 10 days
Restricted stock units  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized compensation cost $ 290
Expected weighted-average period in years of compensation cost to be recognized 11 months 1 day
Restricted Stock  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized compensation cost $ 751
Expected weighted-average period in years of compensation cost to be recognized 2 years 2 months 1 day
XML 69 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) - Stock options - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total fair value of shares vested $ 199 $ 324
Weighted average estimated fair value of shares granted $ 2.16 $ 0.78
XML 70 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 04, 2024
Apr. 05, 2023
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Sep. 15, 2022
Operating Loss Carryforwards [Line Items]              
Operating loss carryforwards subject to expiration         $ 88,200    
Unrecognized tax benefits         344 $ 344  
Proceeds from sale of NOLs, gross $ 8,900            
Proceeds from sale of NOLs $ 700            
Benefit from income taxes   $ 800 $ (798) $ 0      
Loss on sale of NOL   $ 100          
CEND              
Operating Loss Carryforwards [Line Items]              
Fair value market of tax NOLs         $ 36,100    
Effective income tax rate reconciliation         2.54%    
NOL annual limitation         $ 917    
Federal              
Operating Loss Carryforwards [Line Items]              
Net operating loss carryforwards, prior to write down         43,700 33,700  
Net operating loss carryforwards           34,000  
Federal | Research Tax Credit Carryforward              
Operating Loss Carryforwards [Line Items]              
Tax credit carryforward         500    
Federal | CEND              
Operating Loss Carryforwards [Line Items]              
Net operating loss carryforwards         3,600   $ 3,100
Operating loss carryforwards, post acquisition         459    
State | Research Tax Credit Carryforward              
Operating Loss Carryforwards [Line Items]              
Tax credit carryforward         100    
State | CEND              
Operating Loss Carryforwards [Line Items]              
Net operating loss carryforwards             $ 4,300
State | New Jersey              
Operating Loss Carryforwards [Line Items]              
Net operating loss carryforwards         19,400 35,500  
State | California              
Operating Loss Carryforwards [Line Items]              
Net operating loss carryforwards         9,200 9,200  
State | New York              
Operating Loss Carryforwards [Line Items]              
Net operating loss carryforwards         1,900 1,900  
Foreign Tax Authority | CEND              
Operating Loss Carryforwards [Line Items]              
Net operating loss carryforwards         $ 2,400 $ 1,800  
XML 71 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Australia Research and Development Tax Incentive (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Income Tax Holiday [Line Items]    
Income tax incentive receivable $ 1.0 $ 1.0
Minimum    
Income Tax Holiday [Line Items]    
Research tax credit rate 43.50%  
Maximum    
Income Tax Holiday [Line Items]    
Research tax credit rate 48.50%  
XML 72 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Contingencies (Details) - Lingmed Limited
$ in Thousands
Mar. 25, 2024
USD ($)
Loss Contingencies [Line Items]  
Litigation settlement, amount awarded to other party $ 500
Litigation settlement, payment term 30 days
Litigation settlement, future milestone payments 5.00%
Litigation settlement, first milestone payment $ 250
XML 73 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Technology Transfer Agreement (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 15, 2024
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Oct. 03, 2023
Jul. 31, 2023
Investments in and Advances to Affiliates [Line Items]            
Payments to acquire Impilo SAFE $ 100 $ 100 $ 0      
SAFE, valuation cap   $ 30,000        
SAFE, discount rate   80.00%        
Impilo            
Investments in and Advances to Affiliates [Line Items]            
Investment owned (in shares)           766,000
Shares canceled (in shares)         766,000  
Preferred stock, shares issued (in shares)         574,500  
Ownership percentage   38.60%   38.60%    
XML 74 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
License Agreements (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Oct. 03, 2023
Jul. 31, 2023
Dec. 31, 2015
Impilo        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Investment owned (in shares)     766,000  
Sanford Burnham Prebys        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Shares held by third party (in shares) 0      
Sanford Burnham Prebys | Impilo        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Investment owned (in shares)   191,500    
Sanford Burnham Prebys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Shares issued under license agreement (in shares)       382,030
Annual license maintenance fee       $ 10,000
Annual license maintenance fee, year seven       20,000
Potential milestone payments       $ 10,600
Royalties, net of sales       4.00%
Sublicensing fee       25.00%
XML 75 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Research Collaboration and License Agreement (Details) - USD ($)
 1 Months Ended 3 Months Ended
Sep. 14, 2022
Feb. 28, 2021
Mar. 31, 2024
Mar. 31, 2023
Mar. 25, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue from contract     $ 0 $ 0  
Lingmed Limited          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Litigation settlement, future milestone payments         5.00%
Litigation settlement, first milestone payment         $ 250,000
Exclusive License and Collaboration Agreement | Qilu | License          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Contract with customer, liability   $ 10,000,000      
Revenue from contract $ 5,000,000        
Option to terminate   60 days      
Exclusive License and Collaboration Agreement | Qilu | License | Minimum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Variable consideration amounts, milestones   $ 96,000,000      
Percentage of net sale   10.00%      
Percentage of sublicensing revenues   12.00%      
Exclusive License and Collaboration Agreement | Qilu | License | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Variable consideration amounts, milestones   $ 125,000,000      
Percentage of net sale   15.00%      
Percentage of sublicensing revenues   35.00%      
EXCEL 76 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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end XML 77 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 78 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 136 295 1 false 47 0 false 4 false false R1.htm 0000001 - Document - Cover Sheet http://www.caladrius.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY Sheet http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY CONSOLIDATED STATEMENTS OF EQUITY Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 0000008 - Disclosure - The Business Sheet http://www.caladrius.com/role/TheBusiness The Business Notes 8 false false R9.htm 0000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Available-for-Sale-Securities Sheet http://www.caladrius.com/role/AvailableforSaleSecurities Available-for-Sale-Securities Notes 10 false false R11.htm 0000011 - Disclosure - Property and Equipment Sheet http://www.caladrius.com/role/PropertyandEquipment Property and Equipment Notes 11 false false R12.htm 0000012 - Disclosure - Income (Loss) Per Share Sheet http://www.caladrius.com/role/IncomeLossPerShare Income (Loss) Per Share Notes 12 false false R13.htm 0000013 - Disclosure - Fair Value Measurements Sheet http://www.caladrius.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 0000014 - Disclosure - Accrued Liabilities Sheet http://www.caladrius.com/role/AccruedLiabilities Accrued Liabilities Notes 14 false false R15.htm 0000015 - Disclosure - Operating Leases Sheet http://www.caladrius.com/role/OperatingLeases Operating Leases Notes 15 false false R16.htm 0000016 - Disclosure - Stockholders' Equity Sheet http://www.caladrius.com/role/StockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 0000017 - Disclosure - Share-Based Compensation Sheet http://www.caladrius.com/role/ShareBasedCompensation Share-Based Compensation Notes 17 false false R18.htm 0000018 - Disclosure - Income Taxes Sheet http://www.caladrius.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 0000019 - Disclosure - Australia Research and Development Tax Incentive Sheet http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive Australia Research and Development Tax Incentive Notes 19 false false R20.htm 0000020 - Disclosure - Contingencies Sheet http://www.caladrius.com/role/Contingencies Contingencies Notes 20 false false R21.htm 0000021 - Disclosure - Technology Transfer Agreement Sheet http://www.caladrius.com/role/TechnologyTransferAgreement Technology Transfer Agreement Notes 21 false false R22.htm 0000022 - Disclosure - License Agreements Sheet http://www.caladrius.com/role/LicenseAgreements License Agreements Notes 22 false false R23.htm 0000023 - Disclosure - Research Collaboration and License Agreement Sheet http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement Research Collaboration and License Agreement Notes 23 false false R24.htm 0000024 - Disclosure - Subsequent Events Sheet http://www.caladrius.com/role/SubsequentEvents Subsequent Events Notes 24 false false R25.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 25 false false R26.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 26 false false R27.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies 27 false false R28.htm 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies 28 false false R29.htm 9954473 - Disclosure - Available-for-Sale-Securities (Tables) Sheet http://www.caladrius.com/role/AvailableforSaleSecuritiesTables Available-for-Sale-Securities (Tables) Tables http://www.caladrius.com/role/AvailableforSaleSecurities 29 false false R30.htm 9954474 - Disclosure - Property and Equipment (Tables) Sheet http://www.caladrius.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://www.caladrius.com/role/PropertyandEquipment 30 false false R31.htm 9954475 - Disclosure - Income (Loss) Per Share (Tables) Sheet http://www.caladrius.com/role/IncomeLossPerShareTables Income (Loss) Per Share (Tables) Tables http://www.caladrius.com/role/IncomeLossPerShare 31 false false R32.htm 9954476 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.caladrius.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.caladrius.com/role/FairValueMeasurements 32 false false R33.htm 9954477 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.caladrius.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.caladrius.com/role/AccruedLiabilities 33 false false R34.htm 9954478 - Disclosure - Operating Leases (Tables) Sheet http://www.caladrius.com/role/OperatingLeasesTables Operating Leases (Tables) Tables http://www.caladrius.com/role/OperatingLeases 34 false false R35.htm 9954479 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.caladrius.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.caladrius.com/role/StockholdersEquity 35 false false R36.htm 9954480 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.caladrius.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.caladrius.com/role/ShareBasedCompensation 36 false false R37.htm 9954481 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) Sheet http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails Summary of Significant Accounting Policies - Property and Equipment (Details) Details 37 false false R38.htm 9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 38 false false R39.htm 9954483 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) Sheet http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) Details 39 false false R40.htm 9954484 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details) Sheet http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details) Details 40 false false R41.htm 9954485 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details) Sheet http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details) Details 41 false false R42.htm 9954486 - Disclosure - Property and Equipment (Details) Sheet http://www.caladrius.com/role/PropertyandEquipmentDetails Property and Equipment (Details) Details http://www.caladrius.com/role/PropertyandEquipmentTables 42 false false R43.htm 9954487 - Disclosure - Income (Loss) Per Share (Details) Sheet http://www.caladrius.com/role/IncomeLossPerShareDetails Income (Loss) Per Share (Details) Details http://www.caladrius.com/role/IncomeLossPerShareTables 43 false false R44.htm 9954488 - Disclosure - Fair Value Measurements (Details) Sheet http://www.caladrius.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.caladrius.com/role/FairValueMeasurementsTables 44 false false R45.htm 9954489 - Disclosure - Accrued Liabilities (Details) Sheet http://www.caladrius.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://www.caladrius.com/role/AccruedLiabilitiesTables 45 false false R46.htm 9954490 - Disclosure - Operating Leases - Balance Sheet Presentation (Details) Sheet http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails Operating Leases - Balance Sheet Presentation (Details) Details 46 false false R47.htm 9954491 - Disclosure - Operating Leases - Narrative (Details) Sheet http://www.caladrius.com/role/OperatingLeasesNarrativeDetails Operating Leases - Narrative (Details) Details 47 false false R48.htm 9954492 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details) Sheet http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails Operating Leases - Future Minimum Lease Payments (Details) Details 48 false false R49.htm 9954493 - Disclosure - Stockholders' Equity - Equity Issuances (Details) Sheet http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails Stockholders' Equity - Equity Issuances (Details) Details 49 false false R50.htm 9954494 - Disclosure - Stockholders' Equity - Stock Options and Warrants Narrative (Details) Sheet http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails Stockholders' Equity - Stock Options and Warrants Narrative (Details) Details 50 false false R51.htm 9954495 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details) Sheet http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails Stockholders' Equity - Stock Options and Warrants (Details) Details 51 false false R52.htm 9954496 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details) Sheet http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details) Details 52 false false R53.htm 9954497 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Unit Activity (Details) Sheet http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails Stockholders' Equity - Restricted Stock and Restricted Stock Unit Activity (Details) Details 53 false false R54.htm 9954498 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details) Sheet http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails Share-Based Compensation - Share-Based Compensation Expense (Details) Details 54 false false R55.htm 9954499 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details) Sheet http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails Share-Based Compensation - Compensation Cost Not Yet Recognized (Details) Details 55 false false R56.htm 9954500 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) Sheet http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) Details 56 false false R57.htm 9954501 - Disclosure - Income Taxes (Details) Sheet http://www.caladrius.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.caladrius.com/role/IncomeTaxes 57 false false R58.htm 9954502 - Disclosure - Australia Research and Development Tax Incentive (Details) Sheet http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails Australia Research and Development Tax Incentive (Details) Details http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive 58 false false R59.htm 9954503 - Disclosure - Contingencies (Details) Sheet http://www.caladrius.com/role/ContingenciesDetails Contingencies (Details) Details http://www.caladrius.com/role/Contingencies 59 false false R60.htm 9954504 - Disclosure - Technology Transfer Agreement (Details) Sheet http://www.caladrius.com/role/TechnologyTransferAgreementDetails Technology Transfer Agreement (Details) Details http://www.caladrius.com/role/TechnologyTransferAgreement 60 false false R61.htm 9954505 - Disclosure - License Agreements (Details) Sheet http://www.caladrius.com/role/LicenseAgreementsDetails License Agreements (Details) Details http://www.caladrius.com/role/LicenseAgreements 61 false false R62.htm 9954506 - Disclosure - Research Collaboration and License Agreement (Details) Sheet http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails Research Collaboration and License Agreement (Details) Details http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement 62 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: lsta:SaleOfStockAvailableForSalePercentage, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 - lsta-20240331.htm 4 lsta-20240331.htm lsta-20240331.xsd lsta-20240331_cal.xml lsta-20240331_def.xml lsta-20240331_lab.xml lsta-20240331_pre.xml lsta-20240331_g1.jpg lsta-20240331_g2.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 83 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "lsta-20240331.htm": { "nsprefix": "lsta", "nsuri": "http://www.caladrius.com/20240331", "dts": { "inline": { "local": [ "lsta-20240331.htm" ] }, "schema": { "local": [ "lsta-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "lsta-20240331_cal.xml" ] }, "definitionLink": { "local": [ "lsta-20240331_def.xml" ] }, "labelLink": { "local": [ "lsta-20240331_lab.xml" ] }, "presentationLink": { "local": [ "lsta-20240331_pre.xml" ] } }, "keyStandard": 237, "keyCustom": 58, "axisStandard": 20, "axisCustom": 0, "memberStandard": 38, "memberCustom": 7, "hidden": { "total": 13, "http://fasb.org/us-gaap/2023": 7, "http://xbrl.sec.gov/dei/2023": 5, "http://www.caladrius.com/20240331": 1 }, "contextCount": 136, "entityCount": 1, "segmentCount": 47, "elementCount": 541, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 492, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.caladrius.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS", "longName": "0000002 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "unique": true } }, "R6": { "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "unique": true } }, "R8": { "role": "http://www.caladrius.com/role/TheBusiness", "longName": "0000008 - Disclosure - The Business", "shortName": "The Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "lsta:BusinessTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "lsta:BusinessTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.caladrius.com/role/AvailableforSaleSecurities", "longName": "0000010 - Disclosure - Available-for-Sale-Securities", "shortName": "Available-for-Sale-Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.caladrius.com/role/PropertyandEquipment", "longName": "0000011 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.caladrius.com/role/IncomeLossPerShare", "longName": "0000012 - Disclosure - Income (Loss) Per Share", "shortName": "Income (Loss) Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.caladrius.com/role/FairValueMeasurements", "longName": "0000013 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.caladrius.com/role/AccruedLiabilities", "longName": "0000014 - Disclosure - Accrued Liabilities", "shortName": "Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.caladrius.com/role/OperatingLeases", "longName": "0000015 - Disclosure - Operating Leases", "shortName": "Operating Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.caladrius.com/role/StockholdersEquity", "longName": "0000016 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.caladrius.com/role/ShareBasedCompensation", "longName": "0000017 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.caladrius.com/role/IncomeTaxes", "longName": "0000018 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive", "longName": "0000019 - Disclosure - Australia Research and Development Tax Incentive", "shortName": "Australia Research and Development Tax Incentive", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "lsta:ResearchAndDevelopmentTaxIncentiveTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "lsta:ResearchAndDevelopmentTaxIncentiveTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.caladrius.com/role/Contingencies", "longName": "0000020 - Disclosure - Contingencies", "shortName": "Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.caladrius.com/role/TechnologyTransferAgreement", "longName": "0000021 - Disclosure - Technology Transfer Agreement", "shortName": "Technology Transfer Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "lsta:TechnologyTransferAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "lsta:TechnologyTransferAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.caladrius.com/role/LicenseAgreements", "longName": "0000022 - Disclosure - License Agreements", "shortName": "License Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement", "longName": "0000023 - Disclosure - Research Collaboration and License Agreement", "shortName": "Research Collaboration and License Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://www.caladrius.com/role/SubsequentEvents", "longName": "0000024 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true }, "uniqueAnchor": null }, "R29": { "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables", "longName": "9954473 - Disclosure - Available-for-Sale-Securities (Tables)", "shortName": "Available-for-Sale-Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.caladrius.com/role/PropertyandEquipmentTables", "longName": "9954474 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true }, "uniqueAnchor": null }, "R31": { "role": "http://www.caladrius.com/role/IncomeLossPerShareTables", "longName": "9954475 - Disclosure - Income (Loss) Per Share (Tables)", "shortName": "Income (Loss) Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.caladrius.com/role/FairValueMeasurementsTables", "longName": "9954476 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.caladrius.com/role/AccruedLiabilitiesTables", "longName": "9954477 - Disclosure - Accrued Liabilities (Tables)", "shortName": "Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.caladrius.com/role/OperatingLeasesTables", "longName": "9954478 - Disclosure - Operating Leases (Tables)", "shortName": "Operating Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.caladrius.com/role/StockholdersEquityTables", "longName": "9954479 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.caladrius.com/role/ShareBasedCompensationTables", "longName": "9954480 - Disclosure - Share-Based Compensation (Tables)", "shortName": "Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails", "longName": "9954481 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)", "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-46", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-46", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails", "longName": "9954483 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)", "shortName": "Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "unique": true } }, "R40": { "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails", "longName": "9954484 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)", "shortName": "Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails", "longName": "9954485 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)", "shortName": "Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.caladrius.com/role/PropertyandEquipmentDetails", "longName": "9954486 - Disclosure - Property and Equipment (Details)", "shortName": "Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.caladrius.com/role/IncomeLossPerShareDetails", "longName": "9954487 - Disclosure - Income (Loss) Per Share (Details)", "shortName": "Income (Loss) Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-61", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-61", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.caladrius.com/role/FairValueMeasurementsDetails", "longName": "9954488 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-70", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-70", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.caladrius.com/role/AccruedLiabilitiesDetails", "longName": "9954489 - Disclosure - Accrued Liabilities (Details)", "shortName": "Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails", "longName": "9954490 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)", "shortName": "Operating Leases - Balance Sheet Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails", "longName": "9954491 - Disclosure - Operating Leases - Narrative (Details)", "shortName": "Operating Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails", "longName": "9954492 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)", "shortName": "Operating Leases - Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails", "longName": "9954493 - Disclosure - Stockholders' Equity - Equity Issuances (Details)", "shortName": "Stockholders' Equity - Equity Issuances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-77", "name": "lsta:OutstandingStockThreshold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-77", "name": "lsta:OutstandingStockThreshold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails", "longName": "9954494 - Disclosure - Stockholders' Equity - Stock Options and Warrants Narrative (Details)", "shortName": "Stockholders' Equity - Stock Options and Warrants Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-86", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-86", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails", "longName": "9954495 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)", "shortName": "Stockholders' Equity - Stock Options and Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "unique": true } }, "R52": { "role": "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "longName": "9954496 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)", "shortName": "Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-89", "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-89", "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails", "longName": "9954497 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Unit Activity (Details)", "shortName": "Stockholders' Equity - Restricted Stock and Restricted Stock Unit Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-87", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-87", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails", "longName": "9954498 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)", "shortName": "Share-Based Compensation - Share-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails", "longName": "9954499 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)", "shortName": "Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-98", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-98", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails", "longName": "9954500 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)", "shortName": "Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-99", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-99", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.caladrius.com/role/IncomeTaxesDetails", "longName": "9954501 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails", "longName": "9954502 - Disclosure - Australia Research and Development Tax Incentive (Details)", "shortName": "Australia Research and Development Tax Incentive (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-3", "name": "lsta:IncomeTaxIncentiveReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "lsta:IncomeTaxIncentiveReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.caladrius.com/role/ContingenciesDetails", "longName": "9954503 - Disclosure - Contingencies (Details)", "shortName": "Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-122", "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-122", "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.caladrius.com/role/TechnologyTransferAgreementDetails", "longName": "9954504 - Disclosure - Technology Transfer Agreement (Details)", "shortName": "Technology Transfer Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-126", "name": "us-gaap:PaymentsToAcquireOtherInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-126", "name": "us-gaap:PaymentsToAcquireOtherInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.caladrius.com/role/LicenseAgreementsDetails", "longName": "9954505 - Disclosure - License Agreements (Details)", "shortName": "License Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-124", "name": "us-gaap:InvestmentOwnedBalanceShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-131", "name": "lsta:SharesHeldByThirdParty", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "unique": true } }, "R62": { "role": "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails", "longName": "9954506 - Disclosure - Research Collaboration and License Agreement (Details)", "shortName": "Research Collaboration and License Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:CollaborativeArrangementAccountingPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-132", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lsta-20240331.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.caladrius.com/role/AccruedLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Liabilities", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r21" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r20", "r682" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization/accretion on marketable securities", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r96" ] }, "lsta_AccruedGrantFunding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "AccruedGrantFunding", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/AccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/AccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting & tax consulting liabilities", "label": "Accrued Grant Funding", "documentation": "Accrued Grant Funding" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.caladrius.com/role/AccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/AccruedLiabilitiesDetails", "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "totalLabel": "Total", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23" ] }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accrued Liabilities [Abstract]", "label": "Accrued Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/PropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r46", "r143", "r488" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r30", "r31", "r83", "r149", "r483", "r510", "r511" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r13", "r31", "r396", "r399", "r432", "r506", "r507", "r784", "r785", "r786", "r789", "r790", "r791" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r733" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r78", "r682", "r836" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r364", "r365", "r366", "r521", "r789", "r790", "r791", "r821", "r837" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r739" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r739" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r739" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r739" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r61", "r62", "r327" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "lsta_AggregateIntrinsicValueWarrantsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "AggregateIntrinsicValueWarrantsOutstanding", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants Outstanding, Aggregate Intrinsic Value", "label": "Aggregate Intrinsic Value, Warrants Outstanding", "documentation": "Aggregate Intrinsic Value, Warrants Outstanding" } } }, "auth_ref": [] }, "lsta_AggregateIntrinsicValueWarrantsvested": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "AggregateIntrinsicValueWarrantsvested", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Vested, Aggregate Intrinsic Value", "label": "Aggregate Intrinsic Value, Warrants vested", "documentation": "Aggregate Intrinsic Value, Warrants vested" } } }, "auth_ref": [] }, "lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "AggregateIntrinsicValueWarrantsvestedandexpectedtovest", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Vested and expected to vest, Aggregate Intrinsic Value", "label": "Aggregate Intrinsic Value, Warrants vested and expected to vest", "documentation": "Aggregate Intrinsic Value, Warrants vested and expected to vest" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r704", "r715", "r725", "r750" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r707", "r718", "r728", "r753" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r739" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r746" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r711", "r719", "r729", "r746", "r754", "r758", "r766" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r764" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r359", "r371" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r8", "r41", "r44" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r196" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r35" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r387" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r114", "r145", "r171", "r202", "r209", "r213", "r253", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r389", "r393", "r413", "r480", "r547", "r682", "r695", "r810", "r811", "r824" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r139", "r150", "r171", "r253", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r389", "r393", "r413", "r682", "r810", "r811", "r824" ] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/FairValueMeasurementsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Assets, fair value disclosure", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r69" ] }, "lsta_AtTheMarketOfferingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "AtTheMarketOfferingAgreementMember", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ATM Agreement", "label": "At The Market Offering Agreement [Member]", "documentation": "At The Market Offering Agreement" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r222" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r223" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails", "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r219", "r261", "r479" ] }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Abstract]", "label": "Debt Securities, Available-for-Sale [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Less than one year", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r795" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less than one year", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Greater than one year", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r796" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Greater than one year", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value", "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date." } } }, "auth_ref": [ "r796" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 }, "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails", "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Estimated Fair Value", "totalLabel": "Total", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r220", "r261", "r473", "r793" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r761" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r762" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r757" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r757" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r757" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r757" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r757" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r757" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails", "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r354", "r355", "r356", "r357", "r358" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r760" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r759" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r758" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r758" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "lsta_BusinessTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "BusinessTextBlock", "presentation": [ "http://www.caladrius.com/role/TheBusiness" ], "lang": { "en-us": { "role": { "terseLabel": "The Business", "label": "The Business [Text Block]", "documentation": "The Business [Text Block]" } } }, "auth_ref": [] }, "lsta_CENDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "CENDMember", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CEND", "label": "CEND [Member]", "documentation": "CEND" } } }, "auth_ref": [] }, "us-gaap_CaliforniaFranchiseTaxBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CaliforniaFranchiseTaxBoardMember", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "California", "label": "California Franchise Tax Board [Member]", "documentation": "Designated tax department of the government of the state of California." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r33", "r141", "r653" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/FairValueMeasurementsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r34" ] }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-Sale-Securities", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)." } } }, "auth_ref": [ "r792" ] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Cash, Cash Equivalents, and Short-Term Investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": [ "r783" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r33", "r94", "r168" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r94" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": { "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r781", "r832" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r737" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r146", "r147", "r148", "r201", "r288", "r289", "r290", "r292", "r295", "r300", "r302", "r513", "r514", "r515", "r516", "r666", "r772", "r787" ] }, "lsta_ClinicalAndRDRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "ClinicalAndRDRelatedLiabilities", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/AccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.caladrius.com/role/AccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical and R&D related liabilities", "label": "Clinical and R&D Related Liabilities", "documentation": "Clinical and R&D Related Liabilities" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r738" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r738" ] }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementAccountingPolicy", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Milestones, Royalties", "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for collaborative arrangements." } } }, "auth_ref": [ "r126" ] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.caladrius.com/role/LicenseAgreements", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement" ], "lang": { "en-us": { "role": { "terseLabel": "License Agreements", "verboseLabel": "Research Collaboration and License Agreement", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r122", "r124", "r135" ] }, "lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual license maintenance fee", "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee", "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee" } } }, "auth_ref": [] }, "lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual license maintenance fee, year seven", "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven", "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven" } } }, "auth_ref": [] }, "lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential milestone payments", "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product", "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product" } } }, "auth_ref": [] }, "lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales": { "xbrltype": "percentItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties, net of sales", "label": "Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales", "documentation": "Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales" } } }, "auth_ref": [] }, "lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees": { "xbrltype": "percentItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "CollaborativeArrangementRightsAndObligationsSublicensingFees", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sublicensing fee", "label": "Collaborative Arrangement, Rights and Obligations, Sublicensing Fees", "documentation": "Collaborative Arrangement, Rights and Obligations, Sublicensing Fees" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement." } } }, "auth_ref": [ "r820" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r387" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r104", "r689", "r690", "r691", "r692" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies (Note 13)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r26", "r71", "r481", "r534" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.caladrius.com/role/Contingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r103", "r267", "r268", "r647", "r805" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r685", "r686", "r687", "r689", "r690", "r691", "r692", "r789", "r790", "r821", "r835", "r837" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r77" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r77", "r535" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r77" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock outstanding (in shares)", "periodStartLabel": "Common stock, beginning balance (in shares)", "periodEndLabel": "Common stock, ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r77", "r535", "r553", "r837", "r838" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,308,171 and 8,150,635 shares at March 31, 2024 and December 31, 2023, respectively; and outstanding, 8,307,433 and 8,149,897 shares at March 31, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r77", "r482", "r682" ] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValueOutstanding", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, value, outstanding", "label": "Common Stock, Value, Outstanding", "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares." } } }, "auth_ref": [ "r77", "r535" ] }, "lsta_CommonStockWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "CommonStockWarrantsShares", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants, Outstanding, Beginning of Period (in shares)", "periodEndLabel": "Warrants, Outstanding, End of Period (in shares)", "label": "Common Stock Warrants, Shares", "documentation": "Common Stock Warrants, Shares" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r743" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r742" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r744" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r741" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r32", "r156", "r158", "r163", "r475", "r496" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerSoftwareIntangibleAssetMember", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software", "label": "Computer Software, Intangible Asset [Member]", "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks." } } }, "auth_ref": [ "r652", "r802", "r803" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Risks", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r74", "r127" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r67", "r657" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with customer, liability", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r304", "r305", "r316" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r674", "r676", "r834" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r173", "r174", "r284", "r290", "r433", "r654", "r656" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-for-sale Securities [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards subject to expiration", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r8", "r45" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r8", "r45" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r315", "r667", "r668", "r669", "r670", "r671", "r672", "r673" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r315", "r667", "r668", "r669", "r670", "r671", "r672", "r673" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r325", "r329", "r360", "r361", "r363", "r678" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Compensation Cost Related to Nonvested Awards", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r11", "r57" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r699" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r732" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "lsta_EPSAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "EPSAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Basic and diluted loss per share", "label": "EPS [Abstract]", "documentation": "EPS" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Lisata Therapeutics, Inc. common stockholders- basic (in usd per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r164", "r180", "r181", "r182", "r183", "r184", "r189", "r191", "r193", "r194", "r195", "r199", "r404", "r405", "r476", "r497", "r659" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r164", "r180", "r181", "r182", "r183", "r184", "r191", "r193", "r194", "r195", "r199", "r404", "r405", "r476", "r497", "r659" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r35", "r36" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Income (Loss) Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r188", "r196", "r197", "r198" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r415" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate reconciliation", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r375" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit rate", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r818", "r819" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/AccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/AccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Salaries, employee benefits and related taxes", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r362" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected weighted-average period in years of compensation cost to be recognized", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r362" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareDetails", "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails", "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r697" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r697" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r697" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r771" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r697" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r697" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r697" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r697" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r136", "r159", "r160", "r161", "r175", "r176", "r177", "r179", "r185", "r187", "r200", "r254", "r255", "r303", "r364", "r365", "r366", "r380", "r381", "r395", "r396", "r397", "r398", "r399", "r400", "r403", "r416", "r418", "r419", "r420", "r421", "r422", "r432", "r506", "r507", "r508", "r521", "r573" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r250", "r251", "r252" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r250" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r740" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r704", "r715", "r725", "r750" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r701", "r712", "r722", "r747" ] }, "lsta_ExclusiveLicenseAndCollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "ExclusiveLicenseAndCollaborationAgreementMember", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exclusive License and Collaboration Agreement", "label": "Exclusive License and Collaboration Agreement [Member]", "documentation": "Exclusive License and Collaboration Agreement" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r746" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r407", "r408", "r411" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets Measured at Fair Value on Recurring Basis", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r69", "r113" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r285", "r318", "r319", "r320", "r321", "r322", "r323", "r408", "r440", "r441", "r442", "r664", "r665", "r674", "r675", "r676" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r407", "r408", "r409", "r410", "r412" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r406" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r285", "r318", "r323", "r408", "r440", "r674", "r675", "r676" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r285", "r318", "r323", "r408", "r441", "r664", "r665", "r674", "r675", "r676" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r285", "r318", "r319", "r320", "r321", "r322", "r323", "r408", "r442", "r664", "r665", "r674", "r675", "r676" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3." } } }, "auth_ref": [ "r15", "r70" ] }, "lsta_FairValueMarketOfTaxNOLs": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "FairValueMarketOfTaxNOLs", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value market of tax NOLs", "label": "Fair Value Market of Tax NOLs", "documentation": "Fair Value Market of Tax NOLs" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r285", "r318", "r319", "r320", "r321", "r322", "r323", "r440", "r441", "r442", "r664", "r665", "r674", "r675", "r676" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r406", "r412" ] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Minimum Lease Payments", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r256", "r257", "r258", "r259", "r260", "r262", "r263", "r264", "r286", "r300", "r401", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r495", "r663", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r797", "r798", "r799", "r800" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset, useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected amortization, year one", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r100" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected amortization, remainder of fiscal year", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected amortization, year three", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r100" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected amortization, year two", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r100" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired license - intangible, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r99", "r472" ] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCountryMember", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Tax Authority", "label": "Foreign Tax Authority [Member]", "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Remeasurement", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r414" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r708", "r719", "r729", "r754" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r708", "r719", "r729", "r754" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r708", "r719", "r729", "r754" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r708", "r719", "r729", "r754" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r708", "r719", "r729", "r754" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on disposal of fixed assets", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r8" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r87" ] }, "lsta_ImpiloMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "ImpiloMember", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impilo", "label": "Impilo [Member]", "documentation": "Impilo" } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentPolicy", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "In-process Research and Development Expense", "label": "In Process Research and Development, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Less - net income (loss) attributable to noncontrolling interests", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest." } } }, "auth_ref": [ "r65", "r112" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss before benefit from income taxes and noncontrolling interests", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r84", "r118", "r202", "r208", "r212", "r214", "r477", "r491", "r661" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss from equity method investment", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r8", "r85", "r117", "r205", "r249", "r490" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r265", "r266", "r558" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total share-based compensation expense", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r266", "r558" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority, Name [Axis]", "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority, Name [Domain]", "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.caladrius.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r172", "r372", "r376", "r378", "r379", "r382", "r384", "r385", "r386", "r518" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Benefit from income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r120", "r133", "r186", "r187", "r206", "r374", "r383", "r498" ] }, "us-gaap_IncomeTaxHolidayLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxHolidayLineItems", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Holiday [Line Items]", "label": "Income Tax Holiday [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxHolidayTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxHolidayTable", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Holiday [Table]", "label": "Income Tax Holiday [Table]", "documentation": "Income tax-exemptions and reductions which may be granted by a taxing authority for a specified period. Such \"tax holidays\" are typically granted to induce business investment in the tax jurisdiction." } } }, "auth_ref": [ "r111" ] }, "lsta_IncomeTaxIncentiveReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "IncomeTaxIncentiveReceivable", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax incentive receivable", "label": "Income Tax Incentive Receivable", "documentation": "Income Tax Incentive Receivable" } } }, "auth_ref": [] }, "lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued liabilities and other liabilities", "label": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities", "documentation": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r711", "r719", "r729", "r746", "r754", "r758", "r766" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r764" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r700", "r770" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r700", "r770" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r700", "r770" ] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r43", "r468", "r469", "r470", "r472", "r658" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r40", "r42" ] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNet", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Investment income, net", "label": "Investment Income, Net", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r89", "r91" ] }, "us-gaap_InvestmentOwnedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedBalanceShares", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment owned (in shares)", "label": "Investment Owned, Balance, Shares", "documentation": "Number of shares of investment owned." } } }, "auth_ref": [ "r523", "r524", "r586", "r612", "r637", "r687" ] }, "lsta_InvestmentOwnedCanceledShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "InvestmentOwnedCanceledShares", "presentation": [ "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares canceled (in shares)", "label": "Investment Owned, Canceled, Shares", "documentation": "Investment Owned, Canceled, Shares" } } }, "auth_ref": [] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Investments Classified by Contractual Maturity Date", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/FairValueMeasurementsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities - available for sale", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r407" ] }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInAndAdvancesToAffiliatesLineItems", "presentation": [ "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in and Advances to Affiliates [Line Items]", "label": "Investments in and Advances to Affiliates [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Issuance of Stock and Warrants for Services or Claims", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r8" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r102" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "lsta_LegalSettlementCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "LegalSettlementCurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/AccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caladrius.com/role/AccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal settlement", "label": "Legal Settlement, Current", "documentation": "Legal Settlement, Current" } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r428" ] }, "lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet", "label": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]", "documentation": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Lease Payments Under Lease Agreements", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r823" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r431" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r431" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r823" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Amounts representing interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r431" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.caladrius.com/role/OperatingLeases" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r424" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r22", "r171", "r253", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r390", "r393", "r394", "r413", "r533", "r660", "r695", "r810", "r824", "r825" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities, non-controlling interests and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r82", "r116", "r486", "r682", "r788", "r801", "r822" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES, NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r24", "r140", "r171", "r253", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r390", "r393", "r394", "r413", "r682", "r810", "r824", "r825" ] }, "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicenseMember", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License", "label": "License [Member]", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": [ "r814" ] }, "lsta_LingmedLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "LingmedLimitedMember", "presentation": [ "http://www.caladrius.com/role/ContingenciesDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lingmed Limited", "label": "Lingmed Limited [Member]", "documentation": "Lingmed Limited" } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://www.caladrius.com/role/ContingenciesDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.caladrius.com/role/ContingenciesDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement, amount awarded to other party", "label": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "lsta_LitigationSettlementFutureMilestonePaymentsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "LitigationSettlementFutureMilestonePaymentsPercent", "presentation": [ "http://www.caladrius.com/role/ContingenciesDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement, future milestone payments", "label": "Litigation Settlement, Future Milestone Payments, Percent", "documentation": "Litigation Settlement, Future Milestone Payments, Percent" } } }, "auth_ref": [] }, "lsta_LitigationSettlementMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "LitigationSettlementMilestonePayment", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/ContingenciesDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement, first milestone payment", "label": "Litigation Settlement, Milestone Payment", "documentation": "Litigation Settlement, Milestone Payment" } } }, "auth_ref": [] }, "lsta_LitigationSettlementPaymentTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "LitigationSettlementPaymentTerm", "presentation": [ "http://www.caladrius.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement, payment term", "label": "Litigation Settlement, Payment Term", "documentation": "Litigation Settlement, Payment Term" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.caladrius.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r269", "r270", "r271", "r274", "r806", "r807" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.caladrius.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r269", "r270", "r271", "r274", "r806", "r807" ] }, "lsta_LossOnSaleOfNOL": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "LossOnSaleOfNOL", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on sale of NOL", "label": "Loss On Sale of NOL", "documentation": "Loss On Sale of NOL" } } }, "auth_ref": [] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecurities", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": { "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails", "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r72", "r782" ] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r73" ] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Marketable Securities", "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r270", "r271", "r272", "r273", "r324", "r467", "r505", "r525", "r526", "r582", "r601", "r605", "r606", "r634", "r648", "r649", "r662", "r666", "r677", "r684", "r812", "r826", "r827", "r828", "r829", "r830", "r831" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r738" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r738" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r270", "r271", "r272", "r273", "r324", "r467", "r505", "r525", "r526", "r582", "r601", "r605", "r606", "r634", "r648", "r649", "r662", "r666", "r677", "r684", "r812", "r826", "r827", "r828", "r829", "r830", "r831" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r29", "r115", "r171", "r253", "r275", "r277", "r278", "r279", "r282", "r283", "r413", "r485", "r537" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r757" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r815" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r765" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r739" ] }, "lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "NetCarryforwardOperatingLossCarryforwardAnnualLimitation", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NOL annual limitation", "label": "Net Carryforward Operating Loss Carryforward Annual Limitation", "documentation": "Net Carryforward Operating Loss Carryforward Annual Limitation" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r167" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r167" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r94", "r95", "r96" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to Lisata Therapeutics, Inc. common stockholders", "terseLabel": "Net Income (Loss) Attributable to Parent", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r86", "r96", "r119", "r138", "r154", "r157", "r161", "r171", "r178", "r180", "r181", "r182", "r183", "r186", "r187", "r192", "r202", "r208", "r212", "r214", "r253", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r405", "r413", "r493", "r555", "r571", "r572", "r661", "r693", "r810" ] }, "us-gaap_NewJerseyDivisionOfTaxationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewJerseyDivisionOfTaxationMember", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Jersey", "label": "New Jersey Division of Taxation [Member]", "documentation": "Designated tax department of the government of the state of New Jersey." } } }, "auth_ref": [] }, "us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewYorkStateDivisionOfTaxationAndFinanceMember", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New York", "label": "New York State Division of Taxation and Finance [Member]", "documentation": "Designated tax department of the government of the state of New York." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r738" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r708", "r719", "r729", "r746", "r754" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r736" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r735" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r746" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r765" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r765" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Non- Controlling Interest in Subsidiary", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r65", "r303", "r789", "r790", "r791", "r837" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r90" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Activity", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r18" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r202", "r208", "r212", "r214", "r661" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails", "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Operating Lease Liabilities", "verboseLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r426" ] }, "us-gaap_OperatingLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityAbstract", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease Liabilities:", "label": "Operating Lease, Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/AccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/AccruedLiabilitiesDetails", "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities \u2014 current", "verboseLabel": "Accrued liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r426" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, current, balance sheet line item", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r427" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r426" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, noncurrent, balance sheet line item", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r427" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r425" ] }, "lsta_OperatingLeaseRightOfUseAssetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "OperatingLeaseRightOfUseAssetAbstract", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-Use Assets:", "label": "Operating Lease, Right-Of-Use Asset [Abstract]", "documentation": "Operating Lease, Right-Of-Use Asset" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets, balance sheet line item", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": [ "r427" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate for operating leases (percent)", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r430", "r681" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term for operating leases (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r429", "r681" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r64" ] }, "lsta_OperatingLossCarryforwardsBeforeWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "OperatingLossCarryforwardsBeforeWriteDown", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforwards, prior to write down", "label": "Operating Loss Carryforwards, Before Write Down", "documentation": "Operating Loss Carryforwards, Before Write Down" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Line Items]", "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "lsta_OperatingLossCarryforwardsPostAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "OperatingLossCarryforwardsPostAcquisition", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards, post acquisition", "label": "Operating Loss Carryforwards, Post Acquisition", "documentation": "Operating Loss Carryforwards, Post Acquisition" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Table]", "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r63" ] }, "lsta_OptionsVestedweightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "OptionsVestedweightedAverageRemainingContractualTerm", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Vested, Weighted Average Remaining Contractual Term", "label": "Options, Vested, weighted Average Remaining Contractual Term", "documentation": "Options, Vested, weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/AccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.caladrius.com/role/AccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r23" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r144" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized loss on marketable securities", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r151", "r152", "r153" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative translation adjustment arising during the period", "verboseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive loss", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r14", "r19", "r155", "r158", "r162", "r416", "r417", "r422", "r474", "r494", "r784", "r785" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Available for sale securities - net unrealized loss", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r151", "r153", "r248" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r25" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r92" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r738" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r706", "r717", "r727", "r752" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r709", "r720", "r730", "r755" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r709", "r720", "r730", "r755" ] }, "lsta_OutstandingStockThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "OutstandingStockThreshold", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding stock threshold", "label": "Outstanding Stock Threshold", "documentation": "Outstanding Stock Threshold" } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ParentMember", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Total Lisata Therapeutics, Inc. Stockholders' Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r734" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax withholding payments on net share settlement equity awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r165" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r794" ] }, "us-gaap_PaymentsToAcquireOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireOtherInvestments", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Investment in Impilo Therapeutics", "terseLabel": "Payments to acquire Impilo SAFE", "label": "Payments to Acquire Other Investments", "documentation": "Amount of cash outflow to acquire investments classified as other." } } }, "auth_ref": [ "r93" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r737" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r737" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r736" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r746" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r739" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r735" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r76", "r288" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r783" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of marketable securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "lsta_ProceedsFromSaleOfNOLS": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "ProceedsFromSaleOfNOLS", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of NOLs", "label": "Proceeds From Sale of NOLS", "documentation": "Proceeds From Sale of NOLS" } } }, "auth_ref": [] }, "lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of NOLs, gross", "label": "Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross", "documentation": "Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r215", "r471", "r499", "r500", "r501", "r502", "r503", "r504", "r651", "r667", "r683", "r773", "r808", "r809", "r813", "r833" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r215", "r471", "r499", "r500", "r501", "r502", "r503", "r504", "r651", "r667", "r683", "r773", "r808", "r809", "r813", "r833" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r138", "r154", "r157", "r166", "r171", "r178", "r186", "r187", "r202", "r208", "r212", "r214", "r253", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r388", "r391", "r392", "r405", "r413", "r477", "r492", "r520", "r555", "r571", "r572", "r661", "r679", "r680", "r694", "r786", "r810" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r101", "r128", "r131", "r132" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/PropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r102", "r142", "r489" ] }, "us-gaap_PropertyPlantAndEquipmentImpairment": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentImpairment", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Long-lived Assets", "label": "Property, Plant and Equipment, Impairment [Policy Text Block]", "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment." } } }, "auth_ref": [ "r47" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.caladrius.com/role/PropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.caladrius.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r478", "r489", "r682" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r9", "r128", "r131", "r487" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentTables", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r102" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Useful life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r734" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r734" ] }, "lsta_QiluMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "QiluMember", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Qilu", "label": "Qilu [Member]", "documentation": "Qilu" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r270", "r271", "r272", "r273", "r317", "r324", "r355", "r356", "r357", "r443", "r467", "r505", "r525", "r526", "r582", "r601", "r605", "r606", "r634", "r648", "r649", "r662", "r666", "r677", "r684", "r687", "r804", "r812", "r827", "r828", "r829", "r830", "r831" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r270", "r271", "r272", "r273", "r317", "r324", "r355", "r356", "r357", "r443", "r467", "r505", "r525", "r526", "r582", "r601", "r605", "r606", "r634", "r648", "r649", "r662", "r666", "r677", "r684", "r687", "r804", "r812", "r827", "r828", "r829", "r830", "r831" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r701", "r712", "r722", "r747" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r173", "r174", "r284", "r290", "r433", "r655", "r656" ] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept." } } }, "auth_ref": [ "r817" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "lsta_ResearchAndDevelopmentTaxIncentiveTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "ResearchAndDevelopmentTaxIncentiveTextBlock", "presentation": [ "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive" ], "lang": { "en-us": { "role": { "terseLabel": "Australia Research and Development Tax Incentive", "label": "Research and Development Tax Incentive [Text Block]", "documentation": "Research and Development Tax Incentive" } } }, "auth_ref": [] }, "lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate": { "xbrltype": "durationItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "ResearchCollaborationAndLicenseAgreementOptionToTerminate", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option to terminate", "label": "Research Collaboration and License Agreement, Option to Terminate", "documentation": "Research Collaboration and License Agreement, Option to Terminate" } } }, "auth_ref": [] }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Costs", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination." } } }, "auth_ref": [ "r1", "r2", "r75" ] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchMember", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research Tax Credit Carryforward", "label": "Research Tax Credit Carryforward [Member]", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r63" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r702", "r713", "r723", "r748" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r703", "r714", "r724", "r749" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r710", "r721", "r731", "r756" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r35" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareDetails", "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r79", "r108", "r484", "r509", "r511", "r517", "r536", "r682" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r136", "r175", "r176", "r177", "r179", "r185", "r187", "r254", "r255", "r364", "r365", "r366", "r380", "r381", "r395", "r397", "r398", "r400", "r403", "r506", "r508", "r521", "r837" ] }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenue from collaborative arrangement", "terseLabel": "Revenue from contract", "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606." } } }, "auth_ref": [ "r121", "r820" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue excluding taxes", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r203", "r204", "r207", "r210", "r211", "r215", "r216", "r217", "r314", "r315", "r471" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r134", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r650" ] }, "lsta_RevenuePerformanceObligationPercentageOfNetSale": { "xbrltype": "percentItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "RevenuePerformanceObligationPercentageOfNetSale", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of net sale", "label": "Revenue, Performance Obligation, Percentage of Net Sale", "documentation": "Revenue, Performance Obligation, Percentage of Net Sale" } } }, "auth_ref": [] }, "lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues": { "xbrltype": "percentItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "RevenuePerformanceObligationPercentageOfSublicensingRevenues", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of sublicensing revenues", "label": "Revenue, Performance Obligation, Percentage of Sublicensing Revenues", "documentation": "Revenue, Performance Obligation, Percentage of Sublicensing Revenues" } } }, "auth_ref": [] }, "lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable consideration amounts, milestones", "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount", "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount" } } }, "auth_ref": [] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyMember", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty", "label": "Royalty [Member]", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": [ "r814" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r765" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r765" ] }, "lsta_SAFEDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "SAFEDiscountRate", "presentation": [ "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SAFE, discount rate", "label": "SAFE, Discount Rate", "documentation": "SAFE, Discount Rate" } } }, "auth_ref": [] }, "lsta_SAFEValuationCap": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "SAFEValuationCap", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SAFE, valuation cap", "label": "SAFE, Valuation Cap", "documentation": "SAFE, Valuation Cap" } } }, "auth_ref": [] }, "lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate offering amount authorized per agreement", "label": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement", "documentation": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement" } } }, "auth_ref": [] }, "lsta_SaleOfStockAvailableForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "SaleOfStockAvailableForSale", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock available for sale", "label": "Sale of Stock Available for Sale", "documentation": "Sale of Stock Available for Sale" } } }, "auth_ref": [] }, "lsta_SaleOfStockAvailableForSalePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "SaleOfStockAvailableForSalePercentage", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage held by non-affiliates", "label": "Sale of Stock Available for Sale, Percentage", "documentation": "Sale of Stock Available for Sale, Percentage" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock, Name of Transaction [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "lsta_SanfordBurnhamPrebysMember": { "xbrltype": "domainItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "SanfordBurnhamPrebysMember", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sanford Burnham Prebys", "label": "Sanford Burnham Prebys [Member]", "documentation": "Sanford Burnham Prebys" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.caladrius.com/role/AccruedLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-for-sale Securities Reconciliation", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r387" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Share-based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r60" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r250", "r251", "r252" ] }, "us-gaap_ScheduleOfInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInvestmentsTable", "presentation": [ "http://www.caladrius.com/role/TechnologyTransferAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments [Table]", "label": "Schedule of Investments [Table]", "documentation": "Disclosure of information about investments owned by investment company." } } }, "auth_ref": [ "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Units Activity", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r59" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.caladrius.com/role/PropertyandEquipmentDetails", "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails", "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails", "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r326", "r328", "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r354", "r355", "r356", "r357", "r358" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option and Warrants Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r16", "r17", "r58" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Share-based Compensation Awards", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r110" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r48", "r49", "r50", "r51", "r52", "r53", "r54", "r106", "r107", "r108", "r146", "r147", "r148", "r201", "r288", "r289", "r290", "r292", "r295", "r300", "r302", "r513", "r514", "r515", "r516", "r666", "r772", "r787" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r696" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r698" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r88" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r678" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r347" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Forfeited, Weighted average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r347" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r345" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average estimated fair value (in dollars per share)", "verboseLabel": "Granted, Weighted average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r345" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r342", "r343" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, Weighted average grant date fair value (in dollars per share)", "periodEndLabel": "Ending balance, Weighted average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r342", "r343" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r346" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested, Weighted average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r346" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails", "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails", "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r326", "r328", "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r354", "r355", "r356", "r357", "r358" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Weighted Average Contractual Term and Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Options, Expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r341" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Options, Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r340" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r816" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average estimated fair value of shares granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r348" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Outstanding, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options, Outstanding, Beginning of Period (in shares)", "periodEndLabel": "Options, Outstanding, End of Period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r334", "r335" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options, Outstanding. Beginning of Period (in dollars per share)", "periodEndLabel": "Options, Outstanding, End of Period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r334", "r335" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Vested, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r351" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r351" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options, Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r351" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Vested and expected to vest, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r350" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r350" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Vested and expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r350" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails", "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitActivityDetails", "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails", "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r354", "r355", "r356", "r357", "r358" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r339" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Expired (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r341" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r340" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r338" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r325", "r333", "r352", "r353", "r354", "r355", "r358", "r367", "r368", "r369", "r370" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Outstanding, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r109" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Vested and expected to vest, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r350" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value of shares vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r349" ] }, "lsta_SharesHeldByThirdParty": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "SharesHeldByThirdParty", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares held by third party (in shares)", "label": "Shares Held by Third Party", "documentation": "Shares Held by Third Party" } } }, "auth_ref": [] }, "lsta_SharesIssuedUnderLicenseAgreement": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "SharesIssuedUnderLicenseAgreement", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued under license agreement (in shares)", "label": "Shares Issued Under License Agreement", "documentation": "Shares Issued Under License Agreement" } } }, "auth_ref": [] }, "lsta_Sharesvestedandexpectedtovest": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "Sharesvestedandexpectedtovest", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Vested and expected to vest (in shares)", "label": "shares, vested and expected to vest", "documentation": "shares, vested and expected to vest" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r97", "r169" ] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement, Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r27", "r136", "r159", "r160", "r161", "r175", "r176", "r177", "r179", "r185", "r187", "r200", "r254", "r255", "r303", "r364", "r365", "r366", "r380", "r381", "r395", "r396", "r397", "r398", "r399", "r400", "r403", "r416", "r418", "r419", "r420", "r421", "r422", "r432", "r506", "r507", "r508", "r521", "r573" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r175", "r176", "r177", "r200", "r471", "r512", "r522", "r527", "r528", "r529", "r530", "r531", "r532", "r535", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r548", "r549", "r550", "r551", "r552", "r554", "r556", "r557", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r573", "r688" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r175", "r176", "r177", "r200", "r471", "r512", "r522", "r527", "r528", "r529", "r530", "r531", "r532", "r535", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r548", "r549", "r550", "r551", "r552", "r554", "r556", "r557", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r573", "r688" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r705", "r716", "r726", "r751" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r14", "r76", "r77", "r108", "r513", "r573", "r644" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r14", "r108" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r14", "r76", "r77", "r108" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Options, Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r14", "r76", "r77", "r108", "r339" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value of shares issued", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r14", "r76", "r77", "r108" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total Lisata Therapeutics, Inc. stockholders' equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r77", "r80", "r81", "r98", "r537", "r553", "r574", "r575", "r682", "r695", "r788", "r801", "r822", "r837" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r65", "r66", "r68", "r136", "r137", "r160", "r175", "r176", "r177", "r179", "r185", "r254", "r255", "r303", "r364", "r365", "r366", "r380", "r381", "r395", "r396", "r397", "r398", "r399", "r400", "r403", "r416", "r418", "r422", "r432", "r507", "r508", "r519", "r537", "r553", "r574", "r575", "r645", "r694", "r788", "r801", "r822", "r837" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.caladrius.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r105", "r170", "r287", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r301", "r303", "r402", "r576", "r578", "r646" ] }, "us-gaap_StockholdersEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityPolicyTextBlock", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Stockholders' Equity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth_ref": [ "r10", "r577" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r423", "r435" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r423", "r435" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r423", "r435" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.caladrius.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r434", "r436" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r745" ] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforward", "label": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r64" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Axis]", "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r63" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward, Name [Domain]", "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r63" ] }, "lsta_TechnologyTransferAgreementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "TechnologyTransferAgreementAbstract", "lang": { "en-us": { "role": { "label": "Technology Transfer Agreement [Abstract]", "documentation": "Technology Transfer Agreement" } } }, "auth_ref": [] }, "lsta_TechnologyTransferAgreementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "TechnologyTransferAgreementTextBlock", "presentation": [ "http://www.caladrius.com/role/TechnologyTransferAgreement" ], "lang": { "en-us": { "role": { "terseLabel": "Technology Transfer Agreement", "label": "Technology Transfer Agreement [Text Block]", "documentation": "Technology Transfer Agreement" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r737" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r744" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r764" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r766" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.caladrius.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r286", "r300", "r401", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r495", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r797", "r798", "r799", "r800" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r767" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r768" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r766" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r766" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r769" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r767" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r55" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r55" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock, at cost; 738 shares at March 31, 2024 and December 31, 2023", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r28", "r55", "r56" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.caladrius.com/role/LicenseAgreementsDetails", "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r387" ] }, "us-gaap_USStatesAndPoliticalSubdivisionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USStatesAndPoliticalSubdivisionsMember", "presentation": [ "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Municipal debt securities", "label": "US States and Political Subdivisions Debt Securities [Member]", "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments." } } }, "auth_ref": [ "r674", "r834" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r763" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.caladrius.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r373", "r377" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r37", "r38", "r39", "r123", "r125", "r129", "r130" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.caladrius.com/role/IncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r685", "r686", "r689", "r690", "r691", "r692" ] }, "lsta_WarrantsCanceled": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WarrantsCanceled", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Warrants, Forfeited (in shares)", "label": "Warrants Canceled", "documentation": "Warrants Canceled" } } }, "auth_ref": [] }, "lsta_WarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WarrantsExercised", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Warrants, Exercised (in shares)", "label": "Warrants Exercised", "documentation": "Warrants Exercised" } } }, "auth_ref": [] }, "lsta_WarrantsExpired": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WarrantsExpired", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Warrants, Expired (in shares)", "label": "Warrants Expired", "documentation": "Warrants Expired" } } }, "auth_ref": [] }, "lsta_WarrantsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WarrantsGranted", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Granted (in shares)", "label": "Warrants Granted", "documentation": "Warrants Granted" } } }, "auth_ref": [] }, "lsta_WarrantsOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WarrantsOtherDisclosuresAbstract", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Weighted Average Contractual Term and Intrinsic Value", "label": "Warrants Other Disclosures [Abstract]", "documentation": "Warrants Other Disclosures" } } }, "auth_ref": [] }, "lsta_WarrantsVested": { "xbrltype": "sharesItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WarrantsVested", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Vested (in shares)", "label": "Warrants, Vested", "documentation": "Warrants, Vested" } } }, "auth_ref": [] }, "lsta_WarrantsWeightedAverageExercisePriceRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WarrantsWeightedAverageExercisePriceRollForward", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Weighted Average Exercise Price", "label": "Warrants Weighted Average Exercise Price [Roll Forward]", "documentation": "Warrants Weighted Average Exercise Price [Roll Forward]" } } }, "auth_ref": [] }, "lsta_WeightedAverageExercisePriceWarrantsCanceled": { "xbrltype": "perShareItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WeightedAverageExercisePriceWarrantsCanceled", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Forfeited (in dollars per share)", "label": "Weighted Average Exercise Price, Warrants Canceled", "documentation": "Weighted Average Exercise Price, Warrants Canceled" } } }, "auth_ref": [] }, "lsta_WeightedAverageExercisePriceWarrantsExercisable": { "xbrltype": "perShareItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WeightedAverageExercisePriceWarrantsExercisable", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Vested, Weighted Average Exercise Price (in dollars per share)", "label": "Weighted Average Exercise Price, Warrants Exercisable", "documentation": "Weighted Average Exercise Price, Warrants Exercisable" } } }, "auth_ref": [] }, "lsta_WeightedAverageExercisePriceWarrantsExercised": { "xbrltype": "perShareItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WeightedAverageExercisePriceWarrantsExercised", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Exercised (in dollars per share)", "label": "Weighted Average Exercise Price, Warrants Exercised", "documentation": "Weighted Average Exercise Price, Warrants Exercised" } } }, "auth_ref": [] }, "lsta_WeightedAverageExercisePriceWarrantsExpired": { "xbrltype": "perShareItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WeightedAverageExercisePriceWarrantsExpired", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Expired (in dollars per share)", "label": "Weighted Average Exercise Price, Warrants Expired", "documentation": "Weighted Average Exercise Price, Warrants Expired" } } }, "auth_ref": [] }, "lsta_WeightedAverageExercisePriceWarrantsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WeightedAverageExercisePriceWarrantsGranted", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Granted (in dollars per share)", "label": "Weighted Average Exercise Price, Warrants Granted", "documentation": "Weighted Average Exercise Price, Warrants Granted" } } }, "auth_ref": [] }, "lsta_WeightedAverageExercisePriceWarrantsOutstanding": { "xbrltype": "perShareItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WeightedAverageExercisePriceWarrantsOutstanding", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants Outstanding, Beginning of Period (in dollars per share)", "periodEndLabel": "Warrants Outstanding, End of Period (in dollars per share)", "label": "Weighted Average Exercise Price, Warrants Outstanding", "documentation": "Weighted Average Exercise Price, Warrants Outstanding" } } }, "auth_ref": [] }, "lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest": { "xbrltype": "perShareItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Weighted Average Exercise Price, Vested or expected to vest in the future (in dollars per share)", "label": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest", "documentation": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted shares (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r190", "r195" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Basic shares (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r189", "r195" ] }, "lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest": { "xbrltype": "durationItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term", "label": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest", "documentation": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest" } } }, "auth_ref": [] }, "lsta_WeightedAverageRemainingContractualTermwarrantoutstanding": { "xbrltype": "durationItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WeightedAverageRemainingContractualTermwarrantoutstanding", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Outstanding, Weighted Average Remaining Contractual Term", "label": "Weighted Average Remaining Contractual Term warrant outstanding", "documentation": "Weighted Average Remaining Contractual Term warrant outstanding" } } }, "auth_ref": [] }, "lsta_WeightedAverageRemainingContractualTermwarrantsvested": { "xbrltype": "durationItemType", "nsuri": "http://www.caladrius.com/20240331", "localname": "WeightedAverageRemainingContractualTermwarrantsvested", "presentation": [ "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Vested, Weighted Average Remaining Contractual Term", "label": "weighted Average Remaining Contractual Term, warrants vested", "documentation": "weighted Average Remaining Contractual Term, warrants vested" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "SubTopic": "50", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482610/350-50-25-4" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "SubTopic": "40", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482633/350-40-30-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479428/808-10-45-3" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//808/tableOfContent" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r772": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 84 0000320017-24-000031-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000320017-24-000031-xbrl.zip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end XML 86 lsta-20240331_htm.xml IDEA: XBRL DOCUMENT 0000320017 2024-01-01 2024-03-31 0000320017 2024-05-09 0000320017 2024-03-31 0000320017 2023-12-31 0000320017 2023-01-01 2023-03-31 0000320017 us-gaap:CommonStockMember 2022-12-31 0000320017 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000320017 us-gaap:RetainedEarningsMember 2022-12-31 0000320017 us-gaap:TreasuryStockCommonMember 2022-12-31 0000320017 us-gaap:ParentMember 2022-12-31 0000320017 us-gaap:NoncontrollingInterestMember 2022-12-31 0000320017 2022-12-31 0000320017 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000320017 us-gaap:ParentMember 2023-01-01 2023-03-31 0000320017 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000320017 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000320017 us-gaap:CommonStockMember 2023-03-31 0000320017 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000320017 us-gaap:RetainedEarningsMember 2023-03-31 0000320017 us-gaap:TreasuryStockCommonMember 2023-03-31 0000320017 us-gaap:ParentMember 2023-03-31 0000320017 us-gaap:NoncontrollingInterestMember 2023-03-31 0000320017 2023-03-31 0000320017 us-gaap:CommonStockMember 2023-12-31 0000320017 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000320017 us-gaap:RetainedEarningsMember 2023-12-31 0000320017 us-gaap:TreasuryStockCommonMember 2023-12-31 0000320017 us-gaap:ParentMember 2023-12-31 0000320017 us-gaap:NoncontrollingInterestMember 2023-12-31 0000320017 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000320017 us-gaap:ParentMember 2024-01-01 2024-03-31 0000320017 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000320017 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000320017 us-gaap:CommonStockMember 2024-03-31 0000320017 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000320017 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000320017 us-gaap:RetainedEarningsMember 2024-03-31 0000320017 us-gaap:TreasuryStockCommonMember 2024-03-31 0000320017 us-gaap:ParentMember 2024-03-31 0000320017 us-gaap:NoncontrollingInterestMember 2024-03-31 0000320017 us-gaap:FurnitureAndFixturesMember 2024-03-31 0000320017 us-gaap:ComputerEquipmentMember 2024-03-31 0000320017 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-03-31 0000320017 us-gaap:RoyaltyMember 2024-01-01 2024-03-31 0000320017 us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0000320017 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000320017 us-gaap:CommercialPaperMember 2024-03-31 0000320017 us-gaap:CommercialPaperMember 2023-12-31 0000320017 us-gaap:MoneyMarketFundsMember 2024-03-31 0000320017 us-gaap:MoneyMarketFundsMember 2023-12-31 0000320017 us-gaap:USStatesAndPoliticalSubdivisionsMember 2024-03-31 0000320017 us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-12-31 0000320017 us-gaap:ComputerEquipmentMember 2023-12-31 0000320017 us-gaap:LeaseholdImprovementsMember 2024-03-31 0000320017 us-gaap:LeaseholdImprovementsMember 2023-12-31 0000320017 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0000320017 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000320017 us-gaap:WarrantMember 2024-01-01 2024-03-31 0000320017 us-gaap:WarrantMember 2023-01-01 2023-03-31 0000320017 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0000320017 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0000320017 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000320017 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000320017 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000320017 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000320017 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000320017 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000320017 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000320017 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000320017 lsta:AtTheMarketOfferingAgreementMember 2021-06-04 0000320017 us-gaap:SubsequentEventMember lsta:AtTheMarketOfferingAgreementMember 2024-05-01 0000320017 us-gaap:SubsequentEventMember 2024-05-01 0000320017 lsta:AtTheMarketOfferingAgreementMember 2024-03-21 0000320017 lsta:AtTheMarketOfferingAgreementMember 2024-01-01 2024-03-31 0000320017 lsta:AtTheMarketOfferingAgreementMember 2021-06-04 2024-03-31 0000320017 lsta:AtTheMarketOfferingAgreementMember 2021-06-04 2024-03-24 0000320017 2023-01-01 2023-12-31 0000320017 us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0000320017 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0000320017 srt:MinimumMember us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0000320017 srt:MaximumMember us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0000320017 us-gaap:RestrictedStockMember 2023-12-31 0000320017 us-gaap:RestrictedStockMember 2024-03-31 0000320017 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0000320017 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0000320017 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0000320017 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0000320017 2024-03-21 0000320017 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0000320017 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0000320017 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0000320017 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0000320017 us-gaap:EmployeeStockOptionMember 2024-03-31 0000320017 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0000320017 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000320017 us-gaap:DomesticCountryMember 2023-12-31 0000320017 us-gaap:DomesticCountryMember 2022-12-31 0000320017 us-gaap:DomesticCountryMember lsta:CENDMember 2023-12-31 0000320017 us-gaap:DomesticCountryMember lsta:CENDMember 2022-09-15 0000320017 us-gaap:StateAndLocalJurisdictionMember lsta:CENDMember 2022-09-15 0000320017 lsta:CENDMember 2023-01-01 2023-12-31 0000320017 lsta:CENDMember 2023-12-31 0000320017 us-gaap:ForeignCountryMember lsta:CENDMember 2023-12-31 0000320017 us-gaap:ForeignCountryMember lsta:CENDMember 2022-12-31 0000320017 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2023-12-31 0000320017 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2023-12-31 0000320017 us-gaap:StateAndLocalJurisdictionMember us-gaap:NewJerseyDivisionOfTaxationMember 2023-12-31 0000320017 us-gaap:StateAndLocalJurisdictionMember us-gaap:NewJerseyDivisionOfTaxationMember 2022-12-31 0000320017 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember 2023-12-31 0000320017 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember 2022-12-31 0000320017 us-gaap:StateAndLocalJurisdictionMember us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember 2023-12-31 0000320017 us-gaap:StateAndLocalJurisdictionMember us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember 2022-12-31 0000320017 2024-03-04 2024-03-04 0000320017 2023-04-05 2023-04-05 0000320017 srt:MinimumMember 2024-01-01 2024-03-31 0000320017 srt:MaximumMember 2024-01-01 2024-03-31 0000320017 lsta:LingmedLimitedMember 2024-03-25 2024-03-25 0000320017 lsta:LingmedLimitedMember 2024-03-25 0000320017 lsta:ImpiloMember 2023-07-31 0000320017 lsta:ImpiloMember 2023-10-03 0000320017 2024-03-15 2024-03-15 0000320017 lsta:ImpiloMember 2024-03-31 0000320017 lsta:ImpiloMember 2023-12-31 0000320017 lsta:SanfordBurnhamPrebysMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2015-12-31 0000320017 lsta:SanfordBurnhamPrebysMember lsta:ImpiloMember 2023-10-03 0000320017 lsta:SanfordBurnhamPrebysMember 2024-03-31 0000320017 lsta:QiluMember us-gaap:LicenseMember lsta:ExclusiveLicenseAndCollaborationAgreementMember 2021-02-28 0000320017 lsta:QiluMember us-gaap:LicenseMember lsta:ExclusiveLicenseAndCollaborationAgreementMember 2022-09-14 2022-09-14 0000320017 lsta:QiluMember us-gaap:LicenseMember srt:MinimumMember lsta:ExclusiveLicenseAndCollaborationAgreementMember 2021-02-28 0000320017 lsta:QiluMember us-gaap:LicenseMember srt:MaximumMember lsta:ExclusiveLicenseAndCollaborationAgreementMember 2021-02-28 0000320017 lsta:QiluMember us-gaap:LicenseMember lsta:ExclusiveLicenseAndCollaborationAgreementMember 2021-02-01 2021-02-28 shares iso4217:USD iso4217:USD shares pure 0000320017 --12-31 2024 Q1 false http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent P1Y 0.33 10-Q true 2024-03-31 false 001-33650 LISATA THERAPEUTICS, INC. DE 22-2343568 110 Allen Road, 2nd Floor Basking Ridge NJ 07920 908 842-0100 Common Stock, par value $0.001 per share LSTA NASDAQ Yes Yes Non-accelerated Filer true false false 8307433 21805000 22593000 21544000 27942000 4210000 3389000 47559000 53924000 146000 175000 245000 263000 290000 332000 48240000 54694000 1263000 2421000 4070000 4169000 5333000 6590000 164000 210000 5497000 6800000 0.001 0.001 500000000 500000000 8308171 8150635 8307433 8149897 8000 8000 577283000 576971000 738 738 708000 708000 -533482000 -528081000 -104000 -42000 42997000 48148000 -254000 -254000 42743000 47894000 48240000 54694000 3241000 3179000 3360000 3665000 6601000 6844000 -6601000 -6844000 589000 670000 -187000 -13000 402000 657000 -6199000 -6187000 -798000 0 -5401000 -6187000 0 0 -5401000 -6187000 -0.65 -0.65 -0.77 -0.77 8294000 8294000 7987000 7987000 -5401000 -6187000 -13000 -11000 -49000 -12000 -62000 -23000 -5463000 -6210000 7867000 8000 574548000 -29000 -507241000 -708000 66578000 -254000 66324000 -6187000 -6187000 -6187000 132000 589000 589000 589000 -11000 -11000 -11000 -12000 -12000 -12000 7999000 8000 575137000 -52000 -513428000 -708000 60957000 -254000 60703000 8151000 8000 576971000 -42000 -528081000 -708000 48148000 -254000 47894000 -5401000 -5401000 -5401000 157000 312000 312000 312000 -13000 -13000 -13000 -49000 -49000 -49000 8308000 8000 577283000 -104000 -533482000 -708000 42997000 -254000 42743000 -5401000 -6187000 454000 675000 46000 48000 0 -3000 -100000 0 152000 167000 872000 1652000 -41000 -167000 -1243000 -1083000 -7027000 -8196000 18824000 30121000 25360000 34410000 100000 0 6436000 4289000 142000 85000 -142000 -85000 -55000 -7000 -788000 -3999000 22593000 32154000 21805000 28155000 The Business<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lisata Therapeutics, Inc. (together with its subsidiaries, the “Company”) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's lead investigational product candidate, certepetide (LSTA1), is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are expected to be unaffected. Certepetide also has been shown to modify the tumor microenvironment (“TME”), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). The Company and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics. To date, certepetide has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring certepetide as a means to enable a variety of treatment modalities to treat a range of solid tumors more effectively. Currently, certepetide, is the subject of several Phase 2 clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. The Company's goal is to develop and commercialize products that address important unmet medical needs. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of March 31, 2024, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2023 and 2022 included in our 2023 Form 10-K. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div> <div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of March 31, 2024, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2023 and 2022 included in our 2023 Form 10-K. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.</span></div> <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div> <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div>The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div> Summary of Significant Accounting Policies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (“R&amp;D”) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company’s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a “business” as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s intangible asset consists of a single asset, a license agreement with Qilu Pharmaceutical, Co., Ltd. (“Qilu”) acquired in the Company's acquisition of Cend Therapeutics, Inc (the “Cend Merger”), with a value of $0.4 million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $17 thousand for the three months ended March 31, 2024 and $18 thousand for the three months ended March 31, 2023. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable. The projected amortization expense is $71 thousand per year for the next 3.5 years. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three months ended March 31, 2024 and 2023.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company’s collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company’s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March 31, 2024 and March 31, 2023, the Company has not recognized revenue related to milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.</span></div> <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div>Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div> <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div> <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div>The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:<div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:358.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P10Y P3Y P3Y <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div> <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div>The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant. <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div>Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. <div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div> <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (“R&amp;D”) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company’s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div> <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a “business” as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div> 400000 P5Y 17000 18000 The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable. 71000 71000 71000 71000 <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div>If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. 0 0 <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company’s collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company’s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March 31, 2024 and March 31, 2023, the Company has not recognized revenue related to milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.</span></div> 0 0 0 Available-for-Sale-Securities<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,732 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,239 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,221 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,662 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,657 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:360.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,715 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,221 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,657 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,239 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,221 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,732 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,239 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,221 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,662 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,657 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 33750000 0 18000 33732000 37791000 3000 8000 37786000 0 0 0 0 1981000 0 0 1981000 5242000 0 0 5242000 4268000 0 0 4268000 247000 0 0 247000 622000 0 0 622000 39239000 0 18000 39221000 44662000 3000 8000 44657000 <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:360.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,715 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,221 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,657 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 17677000 16715000 21544000 27942000 39221000 44657000 <div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,239 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,221 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 39239000 39221000 0 0 39239000 39221000 Property and Equipment<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:358.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s results included depreciation expense of approximately $29 thousand and $30 thousand for the three months ended March 31, 2024 and 2023, respectively.</span></div> 589000 589000 72000 72000 661000 661000 515000 486000 146000 175000 29000 30000 Income (Loss) Per Share<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024 and 2023, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive in the periods presented. At March 31, 2024 and 2023, the Company excluded the following potentially dilutive securities (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> At March 31, 2024 and 2023, the Company excluded the following potentially dilutive securities (in thousands):<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1454000 1493000 1422000 1424000 354000 237000 Fair Value Measurements<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:116.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,544 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,544 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,677 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,544 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,221 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,715 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,942 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,657 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of accounts payable and accrued expenses approximate fair value as of March 31, 2024 and December 31, 2023, due to the short maturity nature of these items.</span></div> <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:116.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,544 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,544 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,677 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,544 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,221 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,715 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,942 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,657 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 17677000 0 0 17677000 16715000 0 0 16715000 0 21544000 0 21544000 0 27942000 0 27942000 17677000 21544000 0 39221000 16715000 27942000 0 44657000 Accrued Liabilities<div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of March 31, 2024 and December 31, 2023 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:313.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,665 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting &amp; tax consulting liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities — current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,070 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,169 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of March 31, 2024 and December 31, 2023 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:313.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,665 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting &amp; tax consulting liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities — current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,070 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,169 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1324000 2665000 1724000 1046000 92000 57000 500000 0 172000 168000 258000 233000 4070000 4169000 Operating Leases<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-388"><span style="-sec-ix-hidden:f-389">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-394"><span style="-sec-ix-hidden:f-395">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-398"><span style="-sec-ix-hidden:f-399">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the weighted average remaining lease term for our operating lease was 1.5 years, and the weighted average discount rate for our operating lease was 9.625%. As of December 31, 2023, the weighted average remaining lease term for our operating leases was 1.75 years, and the weighted average discount rate for our operating leases was 9.625%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under the lease agreement as of March 31, 2024 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.</span></div> <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-388"><span style="-sec-ix-hidden:f-389">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-394"><span style="-sec-ix-hidden:f-395">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-398"><span style="-sec-ix-hidden:f-399">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 267000 308000 267000 308000 172000 168000 92000 137000 264000 305000 P1Y6M 0.09625 P1Y9M 0.09625 <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under the lease agreement as of March 31, 2024 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 143000 143000 286000 22000 264000 Stockholders' Equity<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At The Market Offering Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright &amp; Co., LLC, as sales agent, in connection with an “at the market offering” under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0 million. As of the date of this filing and so long as the Company’s public float remains below $75.0 million, the Company is subject to limitations pursuant to General Instruction I.B.6 of Form S-3 (the “Baby Shelf Limitation”), which limits the amount the Company can offer to up to one-third of its public float during any trailing 12-month period. Subsequent to the filing of the Company's Registration Statement on Form S-3 (File No. 333-279034) on May 1, 2024, the aggregate market value of its outstanding common stock held by non-affiliates was approximately $26.7 million. Pursuant to the Baby Shelf Limitation, since the aggregate market value of the Company's outstanding common stock held by non-affiliates was below $75.0 million at the time of such S-3 filing, the aggregate amount of securities that the Company is permitted to offer and sell is now $8,915,094, which is equal to one-third of the aggregate market value of our common stock held by non-affiliates as of March 21, 2024. If the Company’s public float exceeds $75.0 million on a future measurement date, it will no longer be subject to the Baby Shelf Limitation. There were no issuances of common stock under the ATM Agreement for the three months ended March 31, 2024. Since inception, the Company has issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2024:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,322,501 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.06</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.42</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,165.50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,453,913 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.18 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2024<br/>or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,443,689 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.22 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.5 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,285,911 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.92 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024 and 2023, the Company issued restricted stock for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"></td><td style="width:322.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">  </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vesting terms of restricted stock issuances are generally between <span style="-sec-ix-hidden:f-476">one</span> and four years.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in non-vested restricted stock for the three months ended March 31, 2024:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"><tr><td style="width:1.0%"></td><td style="width:33.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,775 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(99,686)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229,889 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.67 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024 and 2023, the Company issued restricted stock units for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"></td><td style="width:343.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average estimated fair value of restricted stock units issued for services in the three months ended March 31, 2024 and 2023 was $3.08 and $3.00 per share, respectively. The fair value of the restricted stock units was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in non-vested restricted stock units for the three months ended March 31, 2024:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"><tr><td style="width:1.0%"></td><td style="width:33.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.45 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 50000000 26700000 75000000 8915094 0 64394 270774 The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2024:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,322,501 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.06</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.42</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,165.50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,453,913 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.18 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2024<br/>or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,443,689 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.22 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.5 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,285,911 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.92 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1322501 10.81 P6Y21D 164100 1421744 42.51 P2Y5M1D 0 132575 3.07 0 0 0 0 0 0 0 0 0 0 1163 1165.5 0 0 1453913 9.18 P6Y2M4D 232100 1421744 42.51 P2Y 0 1443689 9.22 P6Y1M28D 231500 1421744 42.51 P2Y 0 1285911 9.92 P5Y9M 215900 1421744 42.51 P2Y 0 <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024 and 2023, the Company issued restricted stock for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"></td><td style="width:322.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">  </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in non-vested restricted stock for the three months ended March 31, 2024:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"><tr><td style="width:1.0%"></td><td style="width:33.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,775 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(99,686)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229,889 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.67 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 203800 159950 628000 480000 P4Y 125775 5.86 203800 3.08 99686 5.22 0 0 229889 3.67 <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024 and 2023, the Company issued restricted stock units for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"></td><td style="width:343.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in non-vested restricted stock units for the three months ended March 31, 2024:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"><tr><td style="width:1.0%"></td><td style="width:33.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.45 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 205300 188850 632000 567000 3.08 3.00 P1Y 112800 3.37 97400 3.08 100000 3.00 0 0 110200 3.45 Share-Based Compensation<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes share-based compensation in the form of stock options, restricted stock, and restricted stock units. The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"></td><td style="width:62.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.319%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March 31, 2024 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.92</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March 31, 2024 and 2023 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:378.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</span></div> The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2024 and 2023 (in thousands):<div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"></td><td style="width:62.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.319%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 86000 187000 368000 488000 454000 675000 <div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March 31, 2024 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.92</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17</span></td></tr></table></div> 371000 290000 751000 P2Y3M10D P0Y11M1D P2Y2M1D <div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March 31, 2024 and 2023 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:378.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 199000 324000 2.16 0.78 Income Taxes<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, the Company had approximately $43.7 million and $33.7 million respectively, of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $88.2 million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in approximately $34.0 million of remaining Federal NOLs as of December 31, 2022. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, Cend Therapeutics, Inc. (“Cend”) had approximately $3.6 million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $3.1 million of Federal and $4.3 million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years. Using a fair market value of $36.1 million and applying an applicable federal rate of 2.54% Cend will have an annual limitation of approximately $917 thousand each year. The Federal NOL of $459 thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation and does not expire. As of December 31, 2023 and 2022, Cend’s wholly owned Australian subsidiary had approximately $2.4 million and $1.8 million, respectively, of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company had federal research and development credit carryforwards of $0.5 million expiring from 2027 through 2034 if unutilized, and state research and development credit carryforwards of $0.1 million, which carryforward indefinitely. Utilization of these credits may be subject to an annual limitation based on changes in ownership.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, the Company had State NOLs available in New Jersey of $19.4 million and $35.5 million, respectively, California of $9.2 million and $9.2 million, respectively, and New York City of $1.9 million and $1.9 million, respectively, to offset future taxable income expiring from 2032 through 2043. The usage of the Company’s NOLs is limited given the change in ownership. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the FASB’s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, the Company’s uncertain tax positions were $344 thousand and $344 thousand, respectively. The uncertain tax positions are due to the acquisition of Cend related to Federal and state credits and certain state </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2020, the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of three to four years from the date of the tax return filing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2024, the Company received final approval from the New Jersey Economic Development Authority (“NJEDA”) under the Technology Business Tax Certificate Transfer Program (“Program”) to sell $8.9 million of its New Jersey net operating losses (“NJ NOLs”), which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $0.7 million. The sale of NJ NOLs resulted in a $0.8 million deferred income tax benefit and a loss on sale of $0.1 million recorded in other income (expense) in the consolidated financial statements.</span></div>On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for tax years beginning on or after January 1, 2023. For tax years beginning after December 31, 2021, the Tax Cuts &amp; Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or 15 years beginning in 2022. Since the Company is in a net operating loss position, the capitalization of research and development costs did not have a material impact on the Company’s results of operations for the year ended December 31, 2023. The Company will continue to monitor the possible future impact of changes in tax legislation. 43700000 33700000 88200000 34000000 3600000 3100000 4300000 36100000 0.0254 917000 459000 2400000 1800000 500000 100000 19400000 35500000 9200000 9200000 1900000 1900000 344000 344000 8900000 700000 800000 100000 Australia Research and Development Tax IncentiveThe Company’s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between 43.5% to 48.5% (depending upon the income tax rate) for qualified research and development activities. As of the three months ended March 31, 2024 and 2023, the Company had $1.0 million and $1.0 million, respectively, recorded as an income tax incentive receivable in prepaid and other current assets in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed. 0.435 0.485 1000000 1000000 Contingencies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. The Company has elected to recognize expense for legal fees as incurred when the legal services are provided.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (“Lingmed”) claiming Lingmed was entitled to a success fee based on Cend’s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend’s response to the complaint was filed on June 6, 2022 and denied all of Lingmed’s material allegations. Lingmed filed an answer to Cend’s response on July 11, 2022, denying all of the Company’s material allegations. On March 25, 2024 the Company entered into a settlement agreement whereby the Company is required to pay Lingmed $0.5 million within 30 days of the effective date and the Company effected payment on April 4, 2024. Lingmed is also entitled to 5.0% of any future milestone payments received by the Company under the license agreement with Qilu in addition to a sum of $250 thousand with respect to the first future milestone received by the Company. On April 9, 2024, pursuant to the parties’ joint request, the Court entered a dismissal with prejudice of the entire action as to all parties and all claims and the matter was settled.</span></div> 500000 P30D 0.050 250000 Technology Transfer Agreement<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impilo Therapeutics </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company entered into a technology transfer agreement with Impilo Therapeutics (“Impilo”) under which the Company transferred its rights to its tumor penetrating nanocomplex (TPN) platform to Impilo. As consideration for the technology transfer, Impilo issued a total of 766,000 shares of its pre-seed preferred stock to the Company. On October 3, 2023 </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in connection with the Sanford Burnham Prebys license agreement (Note 15) Impilo cancelled the original stock certificate for 766,000 shares and reissued 574,500 shares of its pre-seed preferred stock to the Company. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2024, the Company purchased a Simple Agreement for Future Equity ("SAFE") from Impilo for $100,000. As of March 31, 2024 and December 31, 2023 the Company owned 38.6% of Impilo. This investment was expensed under the equity method of accounting for the three months ended March 31, 2024 in other expense,net in the accompanying statement of operations. The SAFE has a valuation cap of $30.0 million and an 80% discount rate.</span></div> 766000 766000 574500 100000 0.386 0.386 30000000 0.80 License Agreements<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (“SBP”) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of certepetide. At the time the license agreement was entered into, Cend’s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6 million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company’s pre-seed preferred stock in Impilo on October 3, 2023. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days’ prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP did not own shares of the Company’s common stock as of March 31, 2024. </span></div>Research Collaboration and License Agreement<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the “Qilu Agreement”) in which Cend granted an exclusive license to Qilu for the development and commercialization of certepetide in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of certepetide in its Territory. In consideration for the license, Qilu made an upfront payment of $10.0 million to Cend, which was recognized as revenue by Cend prior to the Company's acquisition of Cend on September 15, 2022 (the “Cend Merger”). In addition, Cend received and recognized as revenue a $5.0 million development milestone prior to the Cend Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $96.0 million and $125.0 million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2024 the Company entered into a settlement agreement with Lingmed whereby Lingmed is entitled to 5.0% of any future milestone payments received by the Company under the Qilu Agreement, in addition, Lingmed is also entitled to a sum of $250 thousand with respect to the first future milestone received by the Company. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate simultaneously.</span></div> 382030 10000000 20000000 10600000 0.04 0.25 191500 0 10000000 5000000 96000000 125000000 0.10 0.15 0.12 0.35 0.050 250000 P60D Subsequent EventsOn April 15, 2024, the Company’s Board of Directors appointed James Nisco as the Company’s Senior Vice President, Finance and Treasury and Chief Accounting Officer, effective immediately. Effective as of April 15, 2024, Mr. Nisco shall serve as the Company’s principal financial officer and principal accounting officer. false false false false

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